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1. Introduction 
1.1 Brief introduction to HIV and AIDS 
1.1.1. Discovery of AIDS and its causative agent 
In the early 1980s, a new clinical syndrome was discovered among homosexual men 
in  the  United  States  and  in  1981  the  first  article  related  to  AIDS  was  published 
[1].This article reported that there was a random increase in pneumocystis carinii 
pneumonia (PCP), a rare lung infection. The infection was commonly associated with 
immunodeficiency, and many of the patients had very low numbers of CD4+ T-cells 
[1].  In  1982,  the  new  disease  was  called  acquired  immunodeficiency  syndrome 
(AIDS) and was properly defined by the center for disease control (CDC).  
The first indication that AIDS could be caused by a retrovirus came in 1983 when 
scientists  from  the  Pasteur  Institute  of  Paris  isolated  a  new  virus  containing  RT 
activity  from  a  patient  with  lymphoadenopathy  [2].This  virus  was  called 
lymphadenopathy associated virus (LAV). Shortly after, a similar virus was isolated 
from an AIDS patient by an American group [3] and it was evident that the new virus 
was the causative agent of AIDS and was called HTLV-III (human T-cell leukemia 
virus type III). At the same time Levy and coworkers [4] reported the identification of 
retroviruses  named  AIDS-associated  retroviruses  (ARVs)  from  AIDS  patients  with 
known risk groups as well as from symptomatic and some healthy people. In 1986 
the International Committee on Taxonomy of Viruses (ICTV) recommended giving the 
AIDS virus its present name, Human Immunodeficiency virus (HIV) [5]. 
1.1.2. Human Immunodeficiency Virus (HIV) 
According  to  ICTV  classification  system  [6],  HIV  is  grouped  in  the  family, 
Retroviridae;  subfamily  Orthoretrovirinae  and  genus  Lentivirus.  Retroviridae 
comprises groups of RNA viruses which are enveloped and replicate in a host cell via 
the enzyme reverse transcriptase to produce DNA from their RNA genome [7]. This 
DNA is transported to the nucleus and integrated in to the cellular chromosome. The 
genus  Lentivirus  (lenti  =  slow)  consists  of  groups  of  viruses  which  have  long 
incubation  period  until  manifestation  of  disease.  Presently  five  serogroups  are 
recognized designated with the associated type of vertebrae host (primates, sheep   - 2 -  Introduction 
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and goats, horses, cats, and cattle) [6]. HIV belongs to the primate lentiviruses. Two 
species of HIV known to exist: HIV-1 and HIV-2. HIV-1 is the virus that was initially 
discovered and termed LAV; it is more virulent [8], and is the cause of the majority of 
HIV  infections  globally.  HIV-2  has  a  lower  pathogenicity  and  lower  transmission 
capacity compared to HIV-1 and is largely confined to West Africa and countries
 with 
past socio-economical links with Portugal, including southwest
 India [9]. 
Morphologically HIV-1 and HIV-2 have the characteristics of a lentivirus, with a cone 
shaped core and a diameter of about 100 to 200 nm [7]. Projections of envelope 
make the surface appear rough. Tiny spikes made of two envelope glycoproteins, 
gp120 (external surface envelope protein) and gp41 (transmembrane protein) (about 
8 nm) may be dispersed evenly over the surface [7]. The matrix protein just below the 
viral  membrane  forms  the  inner  shell.  Beneath  is  the  capsid  protein  which  is 
concentric and rod-shaped, or shaped like a truncated cone which encloses the viral 
RNA. Deep inside the isometric core, nucleocapsid, two strands of RNA molecules of 
approximately 9.6 kb nucleotide bases, integrase, a protease, ribonuclease, and two 
other proteins, known as p6 and p7 are found [7].  
1.2. Epidemiology of HIV/AIDS 
Since AIDS was first recognized in 1981, it has led to the deaths of more than 25 
million people, making it one of the most destructive diseases in recorded history 
[10]. Globally, the number of people living with HIV is rising due to new infections and 
the beneficial impacts of anti retroviral therapy (Fig. 1). In the year 2008 an estimate 
of 33.4 million [31.1 million–35.8 million] people were living with the virus [10]. 
   
Figure 1 Global estimates of the number of people living with HIV from 1990−2008 (UNAIDS 
2009) [10].   - 3 -  Introduction 
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There is an extreme geographical variation in HIV prevalence within and between 
countries.  In  general  sub-Saharan  Africa  is  the  most  heavily  affected  region, 
accounting for 71% of all new HIV infections in 2008 followed by south and south-
east Asia (Fig. 2). 
 
Figure 2 Estimated number of adults and children newly infected with HIV, 2008 (UNAIDS, 2009) 
[10]. 
1.3. Entry and replication of HIV 
The main cellular receptor for HIV is the CD4 molecule [11]. CD4 is a 55-kd surface 
glycoprotein composed of highly charged cytoplasmic domain, a single hydrophobic 
membrane spanning domain and four distinct extracellular domains, D1 to D4 [12]. Its 
physiological function is to stabilize the interaction between the T-cell receptor on the 
surface  of  T  lymphocytes  and  class  II  major  histocompatibility  complex  (MHC-II) 
molecules on antigen-presenting cells. CD4 is present on a variety of hematopoeitic 
cells, including T lymphocytes, macrophages, dendritic cells and microglial cells in 
the brain. HIV-1 typically enters host cells through the interaction of the viral envelope 
protein, gp120, with CD4. This binding induces a conformational change in gp120 so 
that other regions are exposed that can bind to co-receptors, CXCR4 and CCR5, 
adjacent to the CD4 molecule in the cell membrane [13]. Co-receptor binding further 
induces a conformational change in the transmembrane part of gp41 so that a ‘fusion 
peptide’ is exposed and inserted into the cell membrane and this triggers the fusion 
of the viral envelope to the cell membrane [13].   - 4 -  Introduction 
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Subsequent to internalization and uncoating process, the genome-containing core is 
exposed to the cytoplasm in a form suitable for reverse transcription to be completed 
[14]. The genomic RNA is reverse transcribed into complementary DNA by a virally 
coded enzyme, reverse transcriptase. Viral nucleic acid remains associated with the 
reverse transcriptase and intergrase, in the context of a pre-integration complex, and 
transported to the nucleus by a process that requires ATP [15].  
Once in the nucleus, the viral DNA genome integrates into the host cell genome via 
the  action  of  the  viral  integrase,  leading  to  the  formation  of  a  provirus.  Provirus 
integration  sites  are  random  but  may  be  influenced  by  chromatin  structure  [14]. 
Because the HIV provirus is covalently integrated into the host cell chromosome, it 
represents a stable component that is replicated and transmitted to target cells in 
synchrony with cellular DNA. The proviral DNA also serves as a template for the 
production of viral RNAs that include both genomic RNA molecules for incorporation 
into progeny virions as well as mRNAs for viral protein synthesis. 
1.4. HIV co-receptors and biological phenotypes 
After the identification of CD4 as the major HIV receptor, it was recognized that the 
CD4 receptor alone was neither sufficient nor the sole means of viral entry [7]. Some 
human  cells  expressing  high  levels  of  the  CD4  protein,  including  undifferentiated 
CD4+ monocytes, are not susceptible to HIV infection [16-18]. Some animal cells, 
derived through molecular or somatic cell hybrid techniques to express human CD4 
on the cell surface, could not be infected [18]. For more than a decade, the identity of 
the potential HIV-1 co-receptor remained elusive [19].  
Later,  it  was  demonstrated  that  members  of  the  G  protein-coupled  receptor 
superfamily of seven-transmembrane domain proteins provided the long-sought co-
receptor function [20-23]. The two major co-receptors for HIV infection are CXCR4 
and CCR5. In recognition of the importance of CXCR4 and CCR5 in determining HIV 
tropism,  a  nomenclature  scheme  was  devised  based  on  co-receptor  usage  [19]. 
Isolates that used CCR5 were denoted R5 isolates; strains that preferentially used 
CXCR4 were named X4 viruses; and dual-tropic stains that used both CCR5 and 
CXCR4 were denoted R5/X4 [19].    - 5 -  Introduction 
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Before the discovery of co-receptor usage as a classification system, strains of HIV-1 
were classified on their different biological phenotypes [24] i.e., based on cell tropism, 
replication rate in peripheral blood mononuclear cells (PBMCs), or the cytopathology 
in MT-2 cells [25]. Isolates of HIV which grow rapidly to high titers in cell culture and 
induce the formation of multinucleated giant cells (syncytia) in PBMC and certain cell 
lines such as the MT-2 cell lines has been called rapid/high (R/H) syncytia inducing 
(SI) or MT-2 positive [26]. Other isolates which have a slower growth rate and do not 
induce syncytia (NSI) in PBMC and do not infect cell lines has been called slow/low 
(S/L) non-syncytia inducing (NSI) or MT-2 negative [26].Viruses expressing the first, 
rapid phenotype are often X4 viruses whereas the second, slower phenotypes belong 
to R5 viruses [27]. 
1.5. Genomic organization of HIV-1 
The  basic  genome  organization  of  the  HIV-1  provirus  is  similar  to  all  other 
retroviruses with respect to the three major open reading frames (ORFs) encoding 
the structural proteins gag, pol, env (Fig. 3). Gag and pol are produced from the 
unspliced transcript, whereas env is produced from an mRNA in which an intron is 
spliced out [28]. HIV-1 contains 6 additional genes termed tat, rev, vif, vpr, vpx, and 
nef that are produced from alternative splicing [29]. In total, five 5’-splice sites and 
eleven 3’-splice sites have been identified which give rise to more than 40 different 
mRNAs grouped into three different classes, namely: the unspliced primary transcript 
(∼9 kb), a class of singly spliced RNAs (∼4 kb), and a class of two or multiple spliced 
RNAs (∼2 kb) [28-33]. A brief summary of gene and gene products of HIV is given in 
table 1[7].   - 6 -  Introduction 
___________________________________________________________________ 
 
Figure  3  Landmarks  of  the  HIV-1  genome,  HXB2  strain  (from  Los  Alamos  HIV  database; 
http://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html). 
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Table 1. HIV proteins and their function (Adapted from Ref. no. 7) 
 
1.5.1. HIV-1 gp120 
The gp120 (Fig. 4) is a glycoprotein that is located on the surface of HIV. It contains 
the binding site(s) for cellular receptors and the major antibody-neutralizing domains. 
Gp120 gene is around 1.5 kb long and codes for around 500 amino acids [34]. Three 
gp120s, bound as heterodimers to a transmembrane glycoprotein, gp41, are thought 
to combine in a trimer to form the envelope spike [35].  
By  comparing  the  genetic  sequences  of  the  envelope  gp120  from  HIV-1  virus 
isolates,  five  conserved  (C)  and  five  divergent  or  variable  (V)  regions  have  been 
identified [36-38]. Intra-molecular disulfide bonds in the gp120 glycoprotein result in   - 8 -  Introduction 
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the incorporation of the first four variable regions into large, loop like structures [36]. 
Antibody  binding  studies  and  deletion  mutagenesis  have  indicated  that  the  major 
variable loops are well exposed on the surface of the gp120 glycoprotein [39, 40]. 
The more conserved regions fold into a gp120 core where CD4 binding determinants 
in env map to the C3 and C4 domains of gp 120 [41]. V1/V2, C2 and V3 domains on 
the other hand help to stabilize the association [43]. 
   
Figure 4 Structure of an unliganded simian immunodeficiency virus gp120 core (Adapted from 
Ref. no. 42). 
1.5.2. The HIV-1 V3 loop 
The third variable loop or V3 loop is a part or region occupying the gp120 positions 
296 to 331 relative to HXB2. It is typically 34 to 36 residues in length and encodes a 
surface accessible loop formed by a disulfide bridge between two invariant cysteines. 
It contains an important immunodominant neutralizing domain also called principal 
neutralizing domains (PND) [43]. V3 loop-derived peptides have been found to be 
structurally similar to distinct chemokines, the natural ligands of CCR5 and CXC4 [44] 
which  suggested  that  alternative  V3  conformations  are  responsible  for  selective 
interactions with the co-receptors.   - 9 -  Introduction 
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There  is  a  marked  variability  in  the  amino  acid  sequence  of  the  V3  loop  among 
different  isolates,  especially  in  the  regions  flanking  the  highly  conserved  glycine-
proline-glycine (GPG) central part [45]. The GPG crown (or crest) is situated in the 
center of the neutralizing domain [46] and forms a beta turn, with the flanking regions 
as the two strands of an anti-parallel beta sheet [47]. Sequence changes close to the 
GPG  motif  can  alter  the  stability  of  the  beta  sheet  and/or  alter  the  surface 
accessibility, thereby influencing co-receptor usage [46]. 
 
Figure 5 3D structure of the V3 loop obtained from NMR studies. The GPG (Gly15-Pro16-Gly17) 
sequence is shown at the crown of the loop in green, orange, and green, respectively. The 
disulfide bridge is represented by the two Cys residues in yellow (Cys1-Cys35). Position 25 is 
represented by both Arg (positively charged) and Glu (negatively charged) residues in red blue 
and red, respectively. Position 10 is represented by Lys in blue (positively charged).(Adapt 
from ref. no.48). 
1.6. Genetic diversity of HIV  
One of the earliest and most striking observations made about HIV is the extensive 
genetic variation that the virus has within individual hosts [49]. This variation makes 
HIV one of the fastest evolving of all organisms. Rapid evolution of HIV is the result 
of combination of factors. First, the virus experiences a high rate of mutation, with 
reverse  transcriptase  making  1.1  mutations  (range,  0  to  3)  in  each  viral  genome 
during  one  infection  cycle  [50,  51].  Second,  HIV  has  remarkable  replicatory 
dynamics: with a viral generation time of ~2.5 days and production of ~10
10–10
12 new 
virions each day [52]. Since the HIV genome is an estimated 10
4 base pairs in length 
and  the  baseline  rate  of  viral  production  is  approximately  10
10  virions  per  day, 
millions of viral variants are produced within any infected person in a single day [52].
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Finally, HIV-1 recombination can lead to further viral diversity and occurs when one 
person is co-infected with two separate strains of the virus that are multiplying in the 
same cell. Frequent recombination and natural selection further elevate its rate of 
evolutionary change. 
There are large differences in genetic variation between different genetic regions of 
HIV. The  env  gene, which  is  divided  into 5  variable  regions  (V1-V5)  and 5 more 
constant regions (C1-C5), is particularly variable. There is only a 55% similarity in 
amino acid sequence among HIV isolates for the env gene while it is 82% for gag; 
75% for pol; 83% for vif; 87% for vpr; 74% for rev; 67% for tat; and 77% for nef [7].  
The clinical implications of high genetic variability are extensive. It allows the virus to 
escape the host immune system, develop drug resistance and escape the immunity 
induced by candidate vaccines. Therefore, knowledge about genetic variation of HIV-
1 is important for the design of drugs and vaccines and for improving combination 
therapy.  
1.6.1. Genetic subtypes and groups 
Over the past decades, advances in sequencing technology and expanded disease 
surveillance have allowed researchers to characterize the variation in HIV-1 within 
individual patients and around the world. Phylogenetic analysis of HIV-1 and related 
viruses  from  nonhuman  primates  suggest  at  least  four  independent  transmission 
events in the 20th century spawned four HIV-1 groups: major (M), outlier (O), non 
major and non-outlier (N) and P [53,54,55]. 
Group  M  is  by  far  the  most  prevalent  and  contains  the  vast  majority  of  genetic 
variants. It has been divided into subtypes, denoted with letters, and sub-subtypes, 
denoted with numerals [reviewed in ref. no. 56]. Currently nine subtypes (A-D, F-H, J, 
and K), six sub-subtypes (A1–A4, and F1–F2) of the major group M are recognized 
[reviewed in ref. no. 56].Over the past decade, advances in full-genome sequencing 
of HIV also have led to the identification of 48 circulating recombinant forms (CRFs) 
[57] and a number of unique recombinant forms (URFs). These are the results of 
recombination  between  subtypes  within  a  dually  infected  person,  from  whom  the 
recombinant forms are then passed to other people. The recombinant progeny are 
classified  as  circulating  recombinant  forms  if  they  are  identified  in  three  or  more   - 11 -  Introduction 
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people with no direct epidemiologic linkage; otherwise they are described as unique 
recombinant forms [58]. 
There are clear differences in the geographic distribution of HIV-1 subtypes. In 
Europe, North America and Australia subtype B was the first to be discovered and is 
still the predominant variant, although other subtypes have also been introduced 
through travelling and immigration [59]. In South America, subtype B is the most 
common but subtypes F, C and recombinant CRF12_BF are also found [56]. In Asia 
subtypes B and C are the most common non-recombinant subtypes [56]. However 
the highest degree of genetic diversity is seen in Africa. In sub-Saharan Africa, all 
known HIV-1 subtypes are found to circulate in different regions, with different 
relative frequencies. In Central and West Africa subtype A seem to be the 
predominant form, but all other subtypes have been found in this region together with 
many recombinant forms [56]. In east African countries, such as Uganda, Rwanda, 
Kenya and Tanzania, the epidemic has involved mainly subtypes A and D. Subtype C 
predominates in Southern African countries like Zimbabwe, Zambia ,Malawi, 
Botswana and South Africa [56]. Fig.6 summarizes the subtypes and recombinant 
forms circulating throughout the world. 
 
Figure 6 Current Global Distribution of HIV-1 Subtypes and Recombinant Forms (Adapted from 
Ref. no. 56). 
1.6.2.  Genetic  evolution  of  HIV-1  within  individuals  and  concept  of 
quasispecies 
HIV-1  evolves  over  the  course  of  an  individual’s  infection.  Upon  infection,  the 
individual  has  a  homogenous  viral  population  [60-62].  Stable  viral  population   - 12 -  Introduction 
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equilibrium is found when the initial virus is relatively fit and replicating in a relatively 
constant environment. In this environment a particular genetic variant, regardless of 
its pathogenic capacity, would be preferentially increased [63]. Early in the infection 
the immune response reacts quickly and strongly against common viral variants. An 
HIV-1  specific  immune  response may  lead  to  selection  of  HIV-1  escape  variants, 
whereas the release of cytokines and chemokines, due to a more general immune 
activation, appears to stimulate HIV-1 replication and increase virus levels [64].
 As a 
consequence, the infected individual harbours a population of genetically related but 
non-identical viruses that are under constant change and ready to adapt to changes 
in their environment. These genetically heterogeneous populations of closely related 
genomes are called quasispecies [65] .The viral population diversifies until genomic 
sequences  differ  as  much  as  10-15%  in  the  V3  region.  At  late  AIDS  stage,  the 
genetic diversity diminishes again, probably as a result of immune system failure [66].  
Viral sequence heterogeneity also exits in different body compartments within HIV-1 
infected individuals. As HIV infects different cells and tissues, rare mutants escape 
the immune response and increase in frequency [62]. Tissue compartmentalization is 
evident in the lung [67, 68] genital tract [69, 70] and lymph node [69] but is most 
notable in the brain [71]. Some patients have distinct HIV-1 quasispecies
 phylogenies 
between the brain and blood, while others have quasispecies
 that migrate readily 
between these compartments [72]. 
1.7. Tuberculosis 
1.7.1. The tubercle bacillus 
Tuberculosis or tubercle forming disease is an acute or chronic bacterial infection that 
primarily  attacks  the  lungs,  but  which  may  also  affect  the  kidneys,  bones,  lymph 
nodes, and brain. The disease is caused by Mycobacterium tuberculosis (MTB) first 
discovered by Robert Koch. 
Bacteria of the genus Mycobacterium are acid fast, non-motile and non-sporulated 
rods. They have unusual high content (61-71%) of guanine plus cytosine (G+C) in 
the genomic DNA, and a high lipid content in the wall called mycolic acid. They are 
structurally more closely related to Gram-positive bacteria. However, mycobacteria 
do not fit into the Gram-positive category as the molecules attached to the cell wall 
are lipids rather than proteins or polysaccharides. Frequently, they do not retain the   - 13 -  Introduction 
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crystal  violet  and  appear  as  “ghosts”  after  Gram  staining.  Unlike  Gram-negative 
bacteria, mycobacteria do not have an additional membrane in the outer layers of the 
cell wall. M. tuberculosis divides every 12 to 24 hours. This pace is extremely slow 
compared  to  that  of  most  cultivable  bacteria,  which  duplicate  at  regular  intervals 
ranging from about 15 minutes to one hour. 
Phylogenetically,  Mycobacterium  is  grouped  in  the  suprageneric  rank  of 
actinomycetes  with  other  closely  related  genera  like  Corynebacterium,  Gordona, 
Tsukamurella,  Nocardia,  Rhodococcus  and  Dietzia  [73].  Only  a  few  mycobacteria 
became successful pathogens of higher vertebrates while the rest of them live and 
replicate  freely  in  natural  ecosystems.  Host-dependent  mycobacteria  that  cannot 
replicate  in  the  environment  are  Mycobacterium  leprae,  Mycobacterium 
lepraemurium, Mycobacterium avium subsp. Paratuberculosis, and members of the 
Mycobacterium tuberculosis complex [73].  
Tubercle  bacillus  is  the  generic  name  for  Mycobacterium  tuberculosis  (MTB) 
complex.  The  various  etiologic  agents  of  tuberculosis  (TB)  have  distinct  hosts, 
zoonotic potential and reservoirs. Lineage of the agents of TB is shown below [73]:  
Kingdom       Bacteria 
Phylum       Actinobacteria 
Class                 Actinobacteria 
Subclass               Actinobacteridae 
Order                Actinomycetales 
Suborder       Corynebacterineae 
Family       Mycobacteriaceae 
Genus       Mycobacterium 
Species       M. tuberculosis 
M. bovis 
M. africanum 
M. microti 
"M. canettii” 
1.7.2. Stages of TB infection 
MTB is transmitted from person to person through inhalation of bacteria-carrying air 
droplets. From those infected with the bacteria only 5 to 10% actually develop TB 
symptoms [74]. The disease is manifested in two stages: primary and secondary. In 
Mycobacterium tuberculosis complex    - 14 -  Introduction 
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primary TB, a person becomes infected with the TB bacteria but often experience no 
noticeable  symptoms.  At  this  stage  the  patient  is  not  contagious.  Macrophages, 
ingest the TB bacteria and transport them to the lymph nodes where they may be 
inhibited, destroyed, or continue multiplication. 
If the bacteria multiply, active primary tuberculosis will develop. If the bacteria are 
inhibited,  rather  than  destroyed,  the  immune  cells  and  the  bacteria  form  a  mass 
known as a granuloma or tubercle. On a cellular basis, the immune cells form a wall 
around live and inactive bacteria. As long as the immune system remains strong, the 
bacteria remain encapsulated and inactive for many years. If the immune system 
becomes weakened, the tubercle opens; releasing the bacteria and the infection may 
reactivate  to  secondary  TB.  The  formerly  dormant  bacteria  multiply  and  destroy 
tissue  in  the  lungs.  They  also  may  spread  to  the  rest  of  the  body  via  the  blood 
stream.  
1.7.3. Global burden of TB 
Worldwide, one person out of three is infected with Mycobacterium tuberculosis – two 
billion people in total. TB currently holds the seventh place in the global ranking of 
causes of death [73]. In 2008, there were an estimated 9.4 (range, 8.9–9.9 million) 
million incident cases (equivalent to 139 cases per 100 000 population) of TB globally 
[75]. Most of the estimated number of cases in 2008 occurred in Asia (55%) and 
Africa (30%), with small proportions of cases in the Eastern Mediterranean Region 
(7%), the European Region (5%) and the Region of the Americas (3%) [75]. The 22 
high-burden  countries  (HBCs),  defined  as  the  countries  that  rank  first  to  22nd  in 
terms of absolute numbers of cases and which have received particular attention at 
the global level since 2000, account for 80% of all estimated cases worldwide [73,75].  
Of the 9.4 million incident cases in 2008, an estimated 1.2–1.6 million (13–16%) were 
HIV-positive, with a best estimate of 1.4 million (15%) [75]. From these HIV-positive 
cases, 78% were in the African Region and 13% were in the South-East Asia Region 
[75]. There were an estimated 0.5 million deaths among incident TB cases who were 
HIV-positive [75].    - 15 -  Introduction 
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Figure 7 Global estimates of TB incidence rate in 2008 (Adapted from ref. no. 73).  
1.8. HIV and TB Interaction 
The discovery of modern antibiotic treatment in the middle of 1940’s had significantly 
decreased  the  prevalence  of  TB  at  least  in  the  developed  world.  Following  the 
decline,  most  medical  experts  expected  that  the  disease  would  be  completely 
eliminated in industrialized nations by the year 2010. Paradoxically, the disease re-
emerged in the late ’80s fueled by the HIV/AIDS pandemic [76]. 
A complex biological interplay occurs between M. tuberculosis and HIV-1 in the co-
infected  host  that  results  in  the  worsening  of  both  pathologies.  HIV  promotes 
progression of M. tuberculosis either by endogenous reactivation or exogenous re 
infection. In HIV-infected hosts active TB develops at a yearly rate of 8 % [77, 78]. 
Clinical  and  epidemiological  observations  have  demonstrated  that  HIV  infected 
individuals have a 113 times higher risk of developing active TB upon exposure to 
MTB and 170 times higher risk during AIDS compared with uninfected persons [79].  
On the other hand, the course of HIV-1 infection is also accelerated subsequent to 
the development of TB. Both relative risk of death and rates of development of new   - 16 -  Introduction 
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opportunistic infections are increased in HIV-1/TB co-infection compared with CD4 
cell-matched HIV-1 infected control subjects [80]. 
In  HIV/TB  co-infected  individuals,  there  are  several  signs  of  generalized  immune 
activation  in  the  peripheral  blood  [82]  which  are  quantitatively  more  pronounced 
compared to HIV negative TB patients. In addition, active TB has been shown to 
increase HIV replication [82-84]. An investigation done by Nakata et al., [83] using 
bronchoalveolar lavage (BAL) showed that HIV replication in diseased lung segments 
has a ten fold increase compared to unaffected segments or in patients without lung 
infection. The results suggested a significant correlation between tumour necrosis 
factor α (TNFα) concentrations and viral load [85]. Apart from lung segments, plasma 
RNA in HIV-infected persons showed a 5-160 fold increase in viral load during acute 
phase MTB [82].   - 17 -  Introduction 
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1.9. Aim of the study 
-  To analyze the C2V5 env quasispecies diversity in HIV-1 infected individuals 
with  TB  (HIV-1/TB) during  active  TB and after  two  months  of  intensive TB 
chemotherapy,  in  comparison  to  baseline  CD4+  matched  HIV-1  infected 
individuals  without  tuberculosis  (HIV-1/non  TB)  with  an  effort  to  include 
individuals:  
a.  who came from various geographical regions and were living in 
Germany 
b.  who are natives in Europe 
-  To analyze the C2V5 env quasispecies divergence in HIV-1/TB within two time 
points  (i.e.  during  active  TB  (TP-1)  and  after  two  months  of  intensive  TB 
chemotherapy (TP-2)). 
-  To analyze HIV-1 co-receptor usage profile in quasispecies of HIV-1/TB (at 
TP-1 and TP-2) and HIV-1/ non TB. 
-  To analyze if there is any positive selective pressure in HIV-1/TB (TP-1 and 
TP-2)  and  HIV-1/non  TB  by  calculating  synonymous  and  non  synonymous 
nucleotide substitutions.  
-  To analyze if there is any specific C2V5 env region that is highly variable in 
HIV-1/TB as compared to HIV-1/non TB. 
-  To  analyze  whether  there  is  a  difference  in  the  number  of  N-linked 
glycosylation  sites  along  the  C2V5  env  HIV-1/TB  (at  TP-1  and  TP-2)  in 
comparison to HIV-1/non TB. 
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2. Patients, materials and methods 
2.1 Patients, data and plasma 
2.1.1. Frankfurt HIV cohort 
For this study plasma samples were retrospectively selected from participants in 
Frankfurt HIV cohort. Frankfurt HIV cohort is one of the largest HIV cohorts and 
treatment center in Europe with over 3000 regular patient visits (Fig. 8). It is part 
of the Hospital of Johann Wolfgang Goethe University, Frankfurt am Main, HIV 
Treatment and Research Unit (HIVCENTR).  
 
Figure 8 Patient visits at the HIV Treatment & Research Unit 1984 – 2004 (Adapted from ref no. 
86). 
2.1.2. EPIDEM database 
The  Frankfurt  HIV  Cohort  stores  data  related  to  its  patients  in  Microsoft  Access 
based  database  system  called  EPIDEM.  Data  related  to  patients  in  EPIDEM 
database include a unique EPIDEM ID for each patient, age, sex, country of origin 
(citizenship), HIV history, HIV risk factors, anti retroviral therapy (ART) history, any 
infection diagnosed, CD4 and CD8 cell counts, HIV viral load. Data storage has been 
made by authorized data manager. For this study a small query was written by the 
authorized data personnel to select patient who fulfilled the selection criteria (see 
below).   - 19-  Patients, materials and methods 
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2.1.3. HIVCENTER plasma bank 
Since the year 1996, HIVCENTER plasma bank has stored plasma samples drawn 
from Frankfurt HIVCENTER cohort patients’ in-70
0C deep freezer. All data pertaining 
storage has been saved in computerized system. 
2.1.4. Sample selection criteria 
Using EPIDEM and HIVCENTER plasma bank, plasma samples were selected from 
patients who fulfilled the following selection criteria. 
2.1.4.1. Study subjects 
HIV-1  infected  patients  with  microbiologically  and  clinically  confirmed  active 
tuberculosis:-  
•  who  had  blood  plasma  samples  collected  and  stored  around  the  time  of 
diagnosis for active TB and after 2 months of TB chemotherapy before ART 
initiation 
•  who had clinical and laboratory data in EPIDEM 
•  who took standard tuberculosis treatment after active TB was diagnosed and 
did not take ART at least in the first two months of intensive TB treatment 
2.1.4.2. Control subjects 
HIV-1 positive patients whose CD4 cell count had been matched to those of the study 
subjects(see 2.1.4.1) and had stored plasma samples at that particular time point 
•  who had no obvious active co-infections  
•  who were ART naïve by the time of sampling 
•  who had clinical and laboratory data in EPIDEM   - 20 -  Patients, materials and methods 
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2.2. Materials 
2.2.1. Laboratory equipments      
 Table 2. List of laboratory equipments used during the study. 
Product  Manufacturer 
0.2 ml, 8-strip PCR tubes   Biozym Scientific GmbH, Oldendorf, Germany 
Germany 
0.2ml, 96-strip PCR tubes  Biozym Scientific GmbH, Oldendorf, Germany 
8-cap strips  Biozym Scientific GmbH, Oldendorf, Germany 
96-cap strips  Biozym Scientific GmbH, Oldendorf, Germany 
1.5 ml Safe-Lock Micro centrifuge 
Tube 
Eppendorf, Hamburg, Germany 
96-well plate caps  Applied Biosystems, Darmstadt, Germany 
ABI Prism 3100 Avant sequencer  Applied Biosystems, Darmstadt, Germany 
ABI Prism 3100 AVANT capillary-
Array 50cm 
Applied Biosystems, Darmstadt, Germany 
Lab-Centrifuge  Hettich Zentrifugen, Tuttlingen, Germany 
Empty petri dish Greiner 
(94x16mm) 
Sigma-Aldrich,  Steinheim, Germany 
Electrophoresis accessories  München, Germany 
GREINER 15ml polypropylene 
centrifuge tubes 
Greiner bio one, Germany 
Incubator  Heraeus, Thermoscientific 
Magnetic stirer  GLW Gesellschaft für Laborbedarf GmbH, 
Wuerzburg, Germany 
MicroAmp Optical 96-Well Plates  Applied Biosystems 
Table centrifuge  Eppendorf, Hamburg, Germany 
Thermomixer  Eppendorf, Hamburg, Germany   - 21 -  Patients, materials and methods 
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Thermocycler (TP Basic Gradient)  Biometra, Goettingen, Germany 
Transluminator Biometra T1 2  Biometra, Goettingen, Germany 
Shaker incubator  Infors AG, Bottmingen, Germany 
Disposable gloves  Paul Hartmann, Heidenheim, Germany 
UV Gel Documentation system for 
electrophoresis gels 
PeQlab (Biotechnologia GmbH) 
Vortexer  IKA works Inc Wilmington, NC 
2.2.2. Chemicals 
Table 3. List of chemicals used during the study. 
Product  Manufacturer 
Absolute Ethanol  Sigma-Aldrich,  Steinheim, Germany ; J.T.Baker, 
Stuttgart, Germany 
Ampicillin sodium salt  Sigma-Aldrich, Steinheim, Germany 
ABI Prism 3100 POP-6 Polymer  Applied Biosystems 
Boric acid crystals  Merck, Darmstadt, Germany 
Bromophenol blue  Sigma-Aldrich,  Steinheim, Germany 
Difco
TM Lauria Bertani, miller 
Broth 
Becton Dickinson (BD), Heidelberg Germany 
Difco
TM Lauria Bertani Agar  Becton Dickinson (BD) Heidelberg Germany 
DNA Mass Ladder  Fermentas Life Sciences, Leon-Rot, Germany 
Ethidiumbromid  Sigma-Aldrich, Steinheim, Germany 
Ethylenediaminetetraacetic acid   Merck Darmstadt, Germany 
Glycerol  Roth, Karlsruhe, Germany   - 22 -  Patients, materials and methods 
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2.2.3. Commercial kits, reagents, buffers, enzymes, primers and bacteria 
2.2.3.1. QIAamp Viral RNA mini kit (Cat No 217004)……………… QIAGEN GmbH, 
Hilden, Germany 
Contents: 
QIAamp Spin Columns  
Collection Tubes (2-ml)  
Buffer AVL 
Buffer AW1 
Buffer AW2 
Buffer AVE 
Carrier RNA (poly A)  
Handbook 
2.2.3.2. QIAGEN one step RT-PCR kit (Cat No 210212)…………… QIAGEN GmbH, 
Hilden, Germany 
Contents: 
QIAGEN  OneStep  RT-PCR  Enzyme  Mix  (Omniscript  Reverse  Transcriptase, 
Sensiscript Reverse Transcriptase, and HotStarTaq DNA polymerase) 
QIAGEN OneStep RT-PCR Buffer, 
Q-Solution  
dNTP Mix  
RNase-free water  
Handbook 
HPLC-Water RNAse and DNAse 
free 
Eppendorf, Hamburg, Germany 
Hi-Di Formamide  Applied Biosystems 
Incidin plus  Ecolab,Duesseldorf,Germany 
LE GP Agarose   Biozym Scientific GmbH, Germany 
TRIS  SAFC, Andover, UK   - 23 -  Patients, materials and methods 
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2.2.3.3.  Taq  PCR  core  kit  (Cat  No  203645)……………………………  QIAGEN 
GmbH, Hilden, Germany 
Contents: 
Taq DNA Polymerase  
QIAGEN PCR Buffer 
Q-Solution 
MgCl2 
dNTP Mix  
Handbook  
2.2.3.4. CloneJET
TM PCR cloning kit (Cat No K1232)…….Fermentas Life Sciences, 
Leon-Rot, Germany 
Contents 
PJET1.2/blunt Cloning Vector 
 
Figure 9 Genomic organization of PJET1.2/blunt cloning Vector. 
2x Reaction Buffer 
T4 DNA Ligase 
DNA Blunting Enzyme 
PJET1.2 Forward Sequencing Primer [5’-CGACTCACTATAGGGAGAGCGGC-3’] 
PJET1.2 Reverse Sequencing Primer [5’-AAGAACATCGATTTTCCATGGCAG-3’] 
Control PCR Product 
Water, nuclease free 
2.2.3.5.  Transformation  Aid  Bacterial  Transformation  kit  (Cat  No  K2711) 
……Fermentas Life Sciences, Leon-Rot, Germany   - 24 -  Patients, materials and methods 
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Contents 
C-Medium 
T-Solution (A) 
T-Solution (B) 
2.2.3.6. Gene Jet Plasmid Miniprep kit (Cat No 1222)………………Fermentas Life 
Sciences, Leon-Rot, Germany 
Contents 
 GeneJET
TM Spin Columns assembled with Collection Tubes 
 Resuspension Solution 
 Lysis Solution 
 Neutralization Solution 
 Wash Solution (concentrated) 
 RNase A Solution 
 Elution Buffer 
 Handbook 
2.2.3.7. FastDigest® XbaI (Cat No FD0684) …………………….……Fermentas Life 
Sciences, Leon-Rot, Germany 
Cutting site 
5'...T^C T A G A...3'  
3'...A G A T C^T...5' 
2.2.3.8.  FastDigest®  XhoI  (Cat  No  FD0694)………………………Fermentas  Life 
Sciences, Leon-Rot, Germany 
Cutting site 
5'...C^T C G A G...3'  
3'...G A G C T^C...5' 
2.2.3.9. ABIprism 3100 Avant Sequencing kit …………….. Applied Biosystems 
Contents 
Ready Reaction Mix 
pGEM®-3Zf(+) double-stranded DNA Control Template 
–21 M13 Control Primers (forward) 
BigDye Terminator v1.1/3.1 Sequencing Buffer (5X) 
2.2.3.10. DyeEx 96 Kit (Cat No 63206; Cat No 63183)………………QIAGEN GmbH, 
Hilden, Germany   - 25 -  Patients, materials and methods 
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Contents 
DyeEx 96 Plates  
Waste Collection Plates 
Handbook 
2.2.3.11. PCR primers 
Forward primers: 
C2V5out5  (5′-  AAGACGTTCAATGGRACAGG  3′)  corresponding  to  nucleotide  (nt) 
6915-6934 in HXB2  
C2V5in5 (5′-GCA CAG TACA ATGYACACATGG-3′) corresponding to 6952-6973 nt 
in HXB2 and the same reverse primer (C2V5_3) 
Reverse primer: 
C2V5_3 (5′ CAA TTG TCC CTC ATA TYT CCT CC-3′) corresponding to 7660-7638 
nt in HXB2 
2.2.3.12. TBE-buffer (0.5x working solution) 
5X –TBE stock solution  
108 g Tris 
55g Borate 
40ml, 0.5M EDTA 
1 lt H2O 
pH 8.0 
2.2.3.13. 1.5% Agarose gel 
Agarose gel was made by mixing 1.5g agarose with 100ml TBE buffer in 250 ml 
Erlenmeyer flask and boiling in a microwave oven until all of the small translucent 
Agarose particles were dissolved. After cooling to 60
0C, the gel was poured on to an 
assembled  gel  cassette  with  combs. When  the  agarose  gel  was  solidified,  it  was 
transferred in to fixed gel caster electrophoresis chamber which contained 0.5% TBE 
buffer. A mixture of 5-10µl of the PCR product or RE digest product (depending on 
the type of DNA) in 5µl of loading dye (Bromophenol blue) was loaded on the gel. 
100bp λDNA fragment was used as a molecular weight marker. Electrophoresis run 
at 100 milliamperes (180V) for 1 hour. It was then examined under UV light and 
photographed. Positive results were the presence of right size (measured in base 
pair) band or bands.    - 26 -  Patients, materials and methods 
__________________________________________________________________ 
2.2.3.14. Luria-Bertani (LB) agar plate 
1 L of purified water 
40 g Difco
 TM Lauria Bertani Agar 
Autoclaved 121° C for 15 minutes 
Poured to empty Greiner petri dish.  
Petridish kept at room temperature until solidified and stored at 2-8
0C refrigerator 
until use. 
2.2.3.15. LB-Ampicillin agar plate 
1 L of purified water 
40 g Difco
 TM Lauria Bertani Agar 
Autoclaved 121° C for 15 minutes 
the solution was allowed to cool down to 55° C ; 2ml stock solution (100mg/ml) of 
Ampicillin to final conc. 100 µg/ml was added and poured on to empty Greiner Petri 
dish;  Petridish  kept  at  room  temperature  until  solidified,  and  stored  at  2-8
0C 
refrigerator until use. 
2.2.3.16. Luria-Bertani (LB) broth 
1 L of purified water 
25g Difco
TM Lauria Bertani, miller Broth 
Autoclaved 121° C for 15 minutes 
Stored at room temperature until use 
2.2.3.17. Escherichia coli JM107 
A vial of powder of freeze dried E.coli JM107 culture was received free of charge 
from Fermentas Life Sciences, Leon-Rot, Germany. 0.5ml LB Medium was added 
aseptically and mixed. The mixture was streaked on an LB agar plate and allowed to 
grow over night. A single colony was sub cultured in to 5ml LB media and grown at 
37
0C over night. The next day 25% (i.e., 0.125ml to 0.5 ml) glycerol was added to the 
turbid culture, thoroughly mixed and aliquoted in small vials; kept for 1hr at room 
temperature and stored at -80
0C in a deep freezer until use.   - 27 -  Patients, materials and methods 
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2.2.4. Software and databases 
Table 4. List of software and databases used to analyze and present the data in this study. 
Bioedit (for windows) version 
7.0.9.0 
See ref. no.87 
Consensus Maker  www.hiv.lanl.gov 
Datamonkey   www.datamonkey.org 
Editor  Microsoft Windows XP 
FinchTV 
 
Geospiza; 
http://www.geospiza.com/Products/finchtv.shtml 
Genebank, NCBI  http://www.ncbi.nlm.nih.gov/genbank/ 
Geno2pheno  http://www.geno2pheno.org/ 
Genecutter  HIV sequence database Los Alamos,  
http://www.hiv.lanl.gov/content/sequence/GENE_CUT
TER/cutter.html 
GraphPad Prism version 5.00 for 
Windows 
www.graphpad.com Graph Pad Software, San Diego, 
California USA 
Los Alamos HIV-1 database   www.hiv.lanl.gov 
Microsoft excel 2003  Microsoft, Seattel, Washington 
Microsoft power point 2003  Microsoft 
Microsoft word 2003  Microsoft 
Mega 4  See reference no.98 
NCBI Blast  http://blast.ncbi.nlm.nih.gov/Blast.cgi 
N-glycoSite  www.hiv.lanl.gov 
Shannon Entropy  www.hiv.lanl.gov 
SNAP  www.hiv.lanl.gov 
zt partial Mantel test tool  See reference no.105   - 28 -  Patients, materials and methods 
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2.3. Methods 
2.3.1. HIV-1 RNA isolation from plasma 
HIV-1 RNA was isolated from plasma using QIAamp Viral RNA Mini Kit. QIAamp 
Viral RNA Mini Kit uses the principle of selective binding properties of a silica-gel–
based membrane to bind and isolate RNA through optimum buffering condition.  
For  this  purpose,  plasma  samples  that  were  stored  in  -70
0C  deep  freezer  were 
thawed to room temperature. One milliliter of thawed plasma was ultra-centrifuged at 
maximum speed (20,000g) for one hour. After removing the supernatant, 560µl AVL 
buffer was added on to the pellet, mixed by pulse-vortexing and incubated at room 
temperature  for  10min.  After  the  incubation  period,  560µl  absolute  ethanol  was 
added  and  mixed  very  well.  From  the  total  mix,  each  time  630µl  was  carefully 
pipetted and applied on to QIAamp Mini spin column, centrifuged at 6000g for 1 min 
so  that  all  intact  RNA  could  bind  on  to  the  spin  column.  The  filtrate  containing 
collection tube was discarded and replaced by a new collection tube. When this step 
was completed, the mini spin column was washed two times with 500µl buffer AW1 
and buffer AW2 and centrifuged at 6000g. To completely remove traces of liquid a 
final centrifugation at 20,000g for 3 min was done. 60µl of elution buffer (Buffer AVE) 
was carefully added at the center of the spin column and centrifuged at 6000g for 
3min. The RNA containing tube was kept at -70
0C until further experiments were 
performed. 
2.3.2. HIV-1 C2V5 env reverse transcription and PCR amplification 
QIAGEN One-step RT PCR kit was used for reverse transcription of viral RNA to 
cDNA  and  first  PCR  in  one  tube.  The  QIAGEN  OneStep  RT-PCR  kit  contains 
specially formulated enzymes for both reverse transcription and PCR amplification. 
For this purpose 20µl of eluted RNA was taken and mixed with a master mix. The 
master mix was prepared from 4µl RNase-free water, 10µl 5xQIAGEN One step RT-
PCR Buffer, 2.0µl dNTP mix, 10µl 5x Q-solution, 0.5µl each primers, C2V5out5 and 
C2V5_3, 2µl QIAGEN One Step RT-PCR Enzyme Mix and1µl RNase inhibitor. The 
PCR  condition  for  reverse  transcription  and  PCR  amplification  was,  one  cycle  of 
reverse transcription at 50° C for 30 min, followed by initial PCR activation at 95° C for 
15 min; 40 cycles of denaturation, annealing, and elongation at 95
oC for 30 sec, 55
oC   - 29 -  Patients, materials and methods 
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for 45 sec, and 72
oC for 3 min respectively; followed by 1 cycle of extension at 72
oC 
for 10min and a final holding temperature at 4
 oC. 
2.3.3. HIV-1 C2V5 env semi nested PCR 
Semi nested PCR was performed using Qiagen Taq PCR core kit. PCR reaction was 
carried out in 50µl reaction mixture that contained: 10x QIAGEN PCR Buffer (5µl), 5x 
Q-solution (10µl), dNTPs mix (10 mM each) (1µl), Taq polymerase (0.25µl), C2V5in5 
(0.5µl), C2V5_3 (0.5µl) and 27.75µl distilled water with 5µl of the first PCR product. 
The following amplification condition was used: 1 cycle of denaturation at 94
oC for 3 
min, 40 cycles of denaturation, annealing, and elongation at 95
oC for 30sec, 55
oC for 
45 sec, and 72
oC for 3min respectively followed by 1 cycle of final elongation at 72
oC 
for 10 min and holding it at 4
0C till the next step. 
Presence  of  right  sized  amplified  DNA  was  confirmed  by  electrophoresis  in  1.5% 
agarose gel. 
2.3.3. Molecular cloning 
2.3.3.1. Ligation experiment and Competent cell preparation  
Molecular  cloning  was  performed  using  FERMENTAS  GeneJet  PCR  cloning  and 
Bacterial Transformation Kits. The procedure was as follows: On the first day, frozen 
E.coli JM107 was streaked on LB agar plate and incubated at 37
0C for approximately 
16hrs. On the second day, a colony from the first day culture plate was taken and 
streaked on an LB agar plate and incubated in a similar condition as above. On the 
third day, one or two colonies were picked from the second day culture and mixed 
with a pre-warmed 1.5ml Transform AID C-medium in a 2ml centrifuge tube. The 
tubes were then incubated on a Thermomixer for 2hrs at 37
0C at 1000 rpm. Ligation 
was performed in the mean time under the following condition: A blunting reaction 
was prepared by mixing 10µl 2X Reaction buffer, 2µl PCR product, 5µl nuclease-free 
water  and  1µl  DNA  Blunting  enzyme.  The  reaction  mix  was  vortexed  briefly  and 
incubated at 70
0C for 5min followed by chilling on ice for several seconds. Then a 
ligation reaction was made by adding 1µl PJET1.2 blunt Cloning Vector (50ng/µl), 1µl 
T4 DNA Ligase (5U/µl) on to the blunting reaction mixture. The ligation reaction was 
vortexed briefly, spin centrifuged and incubated for 30 min to 1hr.   - 30 -  Patients, materials and methods 
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2.3.3.2. Transformation 
Ampicillin containing LB agar plates were prewarmed at 37
0C for at least 20min. T-
solutions A and B were thawed and vortexed vigorously. TransformAid
TM T-solution 
was prepared by mixing equal volumes of T-solution (A) and T-solution (B) (500 for 
each 2  transformations)  and  kept  on  ice.  Freshly  prepared bacterial  culture  in  C-
medium (above mentioned) was centrifuged at 10,000g for 1min, supernatant was 
removed and immediately kept on ice and resuspended in 300µl TransformAid
TM T-
Solution. After 5 min incubation on ice, the suspension was centrifuged in a similar 
way  as  above  and  the  supernatant  was  discarded  and  the  pelleted  cells  were 
resuspended in 120µl TransformAid
TM T-Solution and incubated on ice for 5min.  
Five µl of the incubated ligation mixture (mentioned above) was dispensed into a new 
microcentrifuge tubes and kept on ice for 2min. After 2 min, 50µl of the resuspended 
cells  were  added  and  incubated  on  ice  for  5min.  The  mix  was  then  plated  on 
prewarmed ampicillin containing LB agar plates (mentioned above) and incubated at 
37
0C overnight. 
2.3.3.3. Selection and growth of colonies 
After 18 hours of incubation, the LB agar was checked for any colony growth. As 
PJET1.2/blunt  is  a  positive  cloning  vector,  only  bacterial  cells  with  recombinant 
plasmids are able to grow. Therefore each single colony that was grown was picked 
and immersed in an ampicillin containing LB media in 15ml Greiner centrifuge tube 
and incubated overnight at 37
0C, on a 200 rpm shaker. On the next day, the bacterial 
pellet was harvested by centrifugation at 5000g for 5min. 
2.3.3.4. Plasmid miniprep 
Miniprep is a process used in molecular biology to analyze bacterial clones. It is used 
for small scale isolation of plamid DNA from bacteria. The isolation method is based 
on  alkaline  lysis.  For  this  purpose;  we  used  Gene  Jet  Plasmid  Miniprep  kit 
(Fermentas).  First  the  bacterial  pellet  (see  above)  was  resuspended  in  250µl 
Resuspension Solution by vortexing and pipetting up and down. The mix was then 
transferred in to a 1.5ml centrifuge tube and 250µl of Lysis Solution was added and 
mixed thoroughly by inverting the tube up and down until the solution turned to be 
viscous.  Immediately,  350µl  of  Neutralizing  Solution  was  added  and  mixed 
thoroughly  and  centrifuged  at  14,000g  for  5min.  The  supernatant  was  then   - 31 -  Patients, materials and methods 
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transferred to GeneJET
TM spin column by careful pipetting not to disturb the white 
precipitates  (contain  cell  debris  and  chromosomal  DNA).  The  spin  column  was 
centrifuged  for  1min  and  the  filtrate  was  discarded;  washed  two  times  by  adding 
500µl  Wash  buffer  and  centrifuging  at  10,000g  for  one  minute  and  a  final 
centrifugation for 3minutes to remove residual solution. Finally, plasmid DNA was 
eluted by adding 50µl elution buffer at the center of the spin column membrane and 
centrifuging at 10,000g for 3min. The plasmid DNA (clone) was then stored in a 
 -20
0C freezer  
2.3.3.5. Restriction digest and analysis of DNA 
Double digest restriction enzymes (or restriction endonucleases), XhoI and XbaI were 
used to confirm the presence of the right size insert of interest in the PJET1.2 vector. 
For this purpose, 20µl of reaction mix was prepared by mixing 2µl purified plasmid 
DNA, 2µl 10X Fast digestion
TM buffer ,1µl XbaI ,1µl xhoI and 16µl of nuclease-free 
water.  After  gentle  mixing  and  spinning,  the  mix  was  incubated  overnight  on  a 
Thermomixer at 37
0C and 300rpm. By agarose gel (1.5%) the presence of two bands 
with sizes around 650 bp and 2900 bp for insert and plasmid DNA respectively was 
verified. 
Plasmid DNA
Insert  DNA
Plasmid DNA
Insert DNA
 
Figure 10 A typical restriction digest plasmid fragments to verify presence of right size insert 
after cloning.   - 32 -  Patients, materials and methods 
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2.3.4. Sequencing 
All clones that contained right size inserts were sequenced using ABI prism 3100 
Avant  genetic  analyzer.  The  ABI  PRISM  3100-Avant  is  a  four  capillary  genetic 
analyzer that uses a single argon-ion laser. The light from the array is collected by a 
spectrograph system with a CCD camera detector that simultaneously provides low 
noise, full-spectrum data from all four capillaries. To sequence the cloned DNA, first, 
a sequence reaction mix was prepared by mixing 9,4µl deionized water, 4µl v1.1 big 
dye  Terminator  Ready  Reaction  Mix,  4µl  5X  sequencing  buffer,2µl  plasmid  DNA 
(containing insert of interest) and 0,6µl PJET1.2 (forward or backward) primers. This 
mix was subjected to by PCR using the following PCR condition to give the sequence 
product (extension product): 1 cycle of denaturation at 96
oC for 1 min, 25 cycles of 
denaturation, annealing, and elongation at 96
oC for 30 sec, 50
oC for 5 sec, and 60
oC 
for 4min. respectively and a final hold to 4
oC. 
The extension product (sequence product) was then purified using Qiagen DyeEx
TM 
Kit to remove unincorporated dyes. For this purpose, DyeEx 96 plate was taken out 
of the bag and placed on the top of the provided collection plate and centrifuged for 3 
min at 750g. The flow through was discarded and 300µl aquadist was added to each 
well and centrifuged for 3min and the flow through was discarded. 20µl of sequencing 
samples were carefully applied on to the gel bed of each well and centrifuged as 
above. All the flow-through was eluted in MicroAmp Optical 96 Well plate and 10µl 
Hi-Di Formamide was added on to it. The sequence product was transferred to 96 
well  plates  and  denatured  at  95
oC  for  5min.  Finally  the  plate  was  loaded  to  the 
sequencer  with  the  following  running  module:  A  capillary  length  of  50  cm  with 
performance optimized polymer 6(POP6
 TM), an Ultra seq- POP-6
TM default module 
with dye set E mobility file. The result was read using the data extraction software. 
2.3.5. Sequence analysis 
The obtained DNA sequence chromatogram was viewed using FinchTV Version 1.4 
and  edited  manually.  FinchTV  is  a  popular,  freely  downloadable  chromatogram 
viewer  which can be used in operating systems; Linux, Mac OSX, Windows, and 
Solaris. It not only used to view chromatogram but also can be used to edit and 
reverse complement sequences and save as a new file.    - 33 -  Patients, materials and methods 
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The  identity  of  the  sequences  was  confirmed  using  NCBI  BLAST.  BLAST  is  a 
sequence  similarity  searching  program  or  algorithm.  BLAST  compares  query 
sequences such as nucleotide sequence with a library or database of sequences, 
and identify library sequences that resemble the query sequence above a certain 
threshold. NCBI (the National Center for Biotechnology Information) is responsible for 
making available the GenBank DNA sequence database.  
After  confirming  the  identity  of  the  sequences,  multiple  sequence  alignment  was 
performed using Bio edit software package which has an integrated ClustalW. Any 
errors in alignment and confirmation of the proper alignment were made using Los 
Alamos freely available online tool, Genecutter. A brief description of the softwares 
and databases that were used to analyze our data are described below: 
2.3.5.1. Los Alamos HIV database 
Los Alamos HIV database [88] is one of the largest and freely available online HIV 
database under Los Alamos National Laboratory funded by Division of AIDS of the 
National Institute of Allergy and Infectious Diseases. The database contains data on 
HIV  genetic  sequences,  immunological  epitopes,  drug  resistance-associated 
mutations,  and  vaccine  trials.  It  also  gives  access  to  a  large  number  of  online 
bioinformatics tools (software). From this database we retrieved reference sequences 
of all HIV-1 subtypes. Besides, the following online tools were used [72; 89-94]:  
Gene cutter: is a sequence alignment and protein extraction tool. It uses Hmmer, an 
implementation  of  profile  hidden  Markov  models  (profile  HMMs)  for  biological 
sequence analysis [95-97] with a training set of the full-length HIV genome alignment. 
Using this online tool, multiple sequence alignments were done and coding regions 
extracted.  
HIV Sequence Locator: is a tool to find the start and end coordinates of HIV input 
sequence(s) relative to the reference HIV strain HXB2. It shows graphically which 
HIV genes or proteins a sequence covers relative to the reference sequence and 
displays both the nucleotide sequence and protein translation. For this study, this tool 
was used to see if the generated sequences were in the right orientation and if there 
was  any  stop  codon.  Sequences  that  contained  premature  stop  codons  were 
excluded from any further analysis. 
Consensus Maker: this tool was used to generate a consensus sequence for clones 
derived from a patient at a single time point.   - 34 -  Patients, materials and methods 
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Entropy: this tool was used to measure variation in protein sequence alignments. 
N-glycosyte: was used to highlight and tally N-Linked Glycosylation site (Nx [ST]) 
patterns,  where  x  can  be  any  amino  acid)  in  amino  acid  alignments  that  were 
generated. 
SNAP: was used to calculate synonymous and non-synonymous substitution rates. 
2.3.5.2. Molecular evolutionary genetics analysis (MEGA) package 
MEGA:- is a very well known and publicly available standalone software package 
(integrated  tool)  [98].  Its  applications  include  sequence  alignment,  inferring 
phylogenetic  trees,  mining  web-based  databases,  estimating  rates  of  molecular 
evolution,  and  testing  evolutionary  hypotheses.  For  this  particular  study,  MEGA 
version 4 was installed and the following analyses were made:- 
Pairwise  distance  between  sequences:-  evolutionary  distances  in  units  of 
substitutions  per  site  were  calculated  using  Kumura-2  parameter  method  [99]  by 
considering  the  rate  variation  among  sites  had  a  gamma  distribution  (shape 
parameter = 0.5). 
Phylogenetic  tree:-  all  phylogenetic  trees  were  constructed  using  the  neighbour-
joining  method  [99].  This  approach  was  selected  because  other  methods  like 
parsimony  or  maximum  likelihood  could  not  handle  such  a  huge  number  of 
sequences that were generated for this study.  
Bootstrap:- was used to test the percentage of replicate trees in which the associated 
taxa clustered together in 1000 replicates [98]. 
Intra-patient viral diversity:- was calculated by averaging distances within all clone 
sequences of each  sample  as  implemented  by  “within  group  average  calculation” 
option of MEGA. 
Viral  divergence:-  defined  as  the  genetic  distance  difference  between  the  newly 
produced viruses compared to founder viruses. It was calculated by estimating the 
net average distances between the two time point sequence samples. Analyses were 
conducted using the Maximum Composite Likelihood method in MEGA4 [98, 101]. 
The  rate  variation  among  sites  was  modelled  with  a  gamma  distribution  (shape 
parameter  =  0.5).  Codon  positions  included  were  1st+2nd+3rd+Noncoding.  All 
positions  containing  alignment  gaps  and  missing  data  were  eliminated  only  in 
pairwise sequence comparisons (Pairwise deletion option).    - 35 -  Patients, materials and methods 
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Viral diversification:- defined as the change in intra-patient diversity or the difference 
between earlier and later time point intra-patient diversity was analyzed by calculating 
pairwise distance of each clone sequence to a consensus sequence generated. 
2.3.5.3. Phenetic analyses using mantel’s test 
Mantel’s test is a generalized regression permutation procedure which compares two 
distance  matrices  [102].  This  method  is  an  established  method  [102-104]  to 
determine if sequences from any compartment (or time point) shared more genetic 
identity  with  each  other  than  with  sequences  from  other  compartments  (or  time 
points). In the present study, we used Mantel’s test to evaluate if clone sequences 
derived from a patient at a time point shared more genetic identity with each other 
than sample from the other time point. For this purpose, two distance matrices were 
generated. The first matrix consisted of pairwise evolutionary distances generated 
from  all  sequences  obtained  at both  time points, and  the  second  distance  matrix 
consisted of an ideal matrix (Md) of the same dimension as the first, such that: 
                 0 if sequence i is from the same time point as sequence j
 
                                           1
 otherwise 
The test was implemented using the zt partial Mantel test tool [105] using 10,000 to 
100,000 randomization. The hypothesis that there is no genetic identity between two 
time points was rejected if the associated p-value exceeded 0.05. 
2.3.5.4. Datamonkey 
DataMonkey is a webserver of the HyPhy package used for estimating the rates of 
nonsynonymous and synonymous changes at each site in a sequence alignment in 
order to identify sites under positive or negative selection [105]. Data monkey has the 
alternatives  of  three  different  codon-based  maximum  likelihood  methods,  (Single 
Likelihood Ancestor Counting (SLAC) [106], fixed effects likelihood (FEL) [107] and 
random  effects  likelihood  (REL)  [107].  For  this  study  SLAC  was  used  to  detect 
positive selection sites. Multiple sequence alignment of the coding region of the clone 
sequences for each sample was used as a raw data. 
2.3.5.5. Web pssm and geno2pheno 
WebPSSM [108] and geno2pheno [109] are bioinformatic tools for predicting HIV-1 
co-receptor usage from the amino acid sequence of the third variable loop (V3) of the 
envelope gene.  
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2.3.5.6. Nucleotide sequence accession number 
Sequin [110] is a stand-alone software tool developed by the NCBI for submitting and 
updating  entries  to  the  GenBank,  EMBL,  or  DDBJ  sequence  databases. 
Sequin.win.exe  version  10  was  downloaded  and  sequences  were  annotated  and 
have been deposited in Genebank.  
2.3.6. Statistical analysis 
Student’s t-test, Man-Whitney U test, Wilcoxon rank sum test and linear correlations 
were calculated using Graph Pad Prism version 5.00 for Windows.  - 37 -  Results 
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3. Results 
3.1. Subjects and specimen collection  
Using EPIDEM, all microbiologically confirmed active TB diagnosed patients from the 
year  1996  to  2006  who  had  follow-up  and  properly  stored  plasma  samples  were 
selected. Only eight TB patients had fulfilled the criteria of selection, [HIV-1/TB, n = 8] 
(subject ID: TB-1 to TB-8) (Table 5). Five of the HIV-1/TB had pulmonary TB, 2 extra 
pulmonary and 1 both pulmonary and extra pulmonary.  
Seven HIV-1/TB patients were ART naïve when they were diagnosed for active TB. 
One patient (TB-5) was diagnosed with active TB 103 days after ART initiation; thus 
ART treatment was interrupted for TB treatment of this patient for approximately 17 
weeks. Second time point samples were obtained for six of the eight patients (TB-1, 
TB-2,  TB-3,  TB-5,  TB-6,  and  TB-7)  at  least  after  2  months  of  antituberculous 
chemotherapy and before initiation of ART. Currently all patients are taking ART.  
As controls, an equal number of HIV-1 infected, baseline CD4 cell count and CDC 
HIV staging matched patients without history of active TB from the same cohort [HIV-
1/non TB, n = 8] (subject ID: NTB-1 to NTB-8) were selected (Table 5). Efforts were 
made to exclude patients with co-infections. While we excluded patients who had 
history of TB based on the results of ELISPOT TB, it was difficult to find patients free 
of all possible co-infections. Five of HIV-1/non TB did not have any recorded co-
infections; the residual three, as analyzed only later on had minor infections like oral 
candidiasis and Toxocara canis after the time of sampling. All control patients were 
ART naïve at the first time point of sampling. However, second time point sampling of 
HIV-1/non  TB  was  not  possible  because  of  the  immediate  start  of  HAART  which 
lowered HIV viral load to very low level.  
The country of origin for four of the HIV-1/TB patients was from European Union (EU) 
and the rest four immigrated from East and North Africa. Four of HIV-1/non TB were 
from EU, three from East Africa and one from Latin America. For all patients the 
exact date of HIV-1 infection is not known. From the records it is suspected that all 
patients had more than two years of HIV-1 infection history. 
The mean age for HIV-1/TB was 42 years (range 29 to 58), mean CD4 cell count was 
112 cells/µl (range 12 to 266), and mean HIV-1 viral load was 864,750 copies/ml   - 38 -  Results 
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(range 361,000 to 2,200,000). For HIV-1/non TB group the mean age was 36 years 
(range 26 to 59), mean CD4 cell count was 134 cells/µl (range 24 to 266), and mean 
HIV-1  viral  load  was  124,405  copies/ml  (range  3,560  to  675,000).  There  was  a 
significantly  elevated  HIV-1  viral  load  (unpaired  t-test,  p  <  0.05)  in  HIV-1/TB  as 
compared to HIV-1/non TB (Fig. 11). Elevated viral load for HIV-1/TB did not decline 
in the second time point follow-up (Wilcoxon rank sum test, p = 0.2) Most of HIV-1/TB 
patients didn’t show a decline in CD4 cell count during treatment for active TB (Fig. 
12). Patients of African origin (n=4) had a significantly higher CD4 cell count when 
they developed active tuberculosis as compared to European origin patients (n=4) 
(unpaired t-test, p <0.05).  
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Table 5. Clinical and routine laboratory data of the study participants.   - 40 -  Results 
________________________________________________________________ 
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Figure 11 Box and whisker plot, showing statistically significant difference in HIV-1 viral 
load (copies/ml) for HIV-1/TB compared to HIV-1/ non TB.  
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Figure 12 Line graph  showing CD4 cell count of HIV-1/TB patients during diagnosis of 
active TB (time point-1, TP- 1) and after intensive TB chemotherapy (time point-2, TP-2). 
3.2. Cloning and sequencing 
A total of 360 clones (Table 6) encompassing 684bp C2V5 env (Fig.13) were 
sequenced. Sequences have been deposited in Genebank NCBI database with 
accession number GQ390435 to GQ390793.   - 41 -  Results 
________________________________________________________________ 
Figure 13 Genomic map of HIV-1 C2V5 env region (HXB-2 numbering) that was sequenced 
and analyzed in the study. 
Table 6. Number of C2V5 env clones generated and sequenced, from HIV-1/TB and HIV-1 
non TB. 
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3.3. Phylogenetic tree  
Neighbor-Joining  trees  were  constructed  to  verify  clustering  pattern  of  clonal 
sequences  and  to  determine  HIV-1  subtypes  (Fig.14).  In  the  HIV-1/TB,  three 
patients were infected with HIV-1 subtype C and the rest carried HIV-1 subtype 
B. In the HIV-1/non TB group, three patients were infected with HIV-1 subtype C, 
a further three  with  HIV-1  subtype  B, and  two  patients  with  HIV-1 subtype  A 
virus. Based on the country of origin, all HIV-1 subtype C patients were from East 
Africa. 
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 Figure 14 Neighbor-Joining tree showing the subtype and monophyletic clustering of all 
quasispecies for HIV-1/TB at two time points of follow-up (solid lines) and CD4 matched 
HIV-1/non TB (broken lines). Trees were drawn based on the Kimura-2 parameter method. 
Reference  subtypes  from  Los  Alamos  HIV  database  were  included  for  subtype 
determination. Bootstrap values in percent are indicated near the branches. The scale bar 
for the branch length represents 0.05 substitutions per nucleotide site. TP_1 = time point 1 
and TP_2 = time point 2.   - 43 -  Results 
________________________________________________________________ 
3.4. Phenotype prediction 
The co-receptor usage of each HIV-1 quasisipecies was predicted using WEB 
PSSM and verified by Geno2pheno. 77 out of 360 clonal sequences (21.3%) 
were X4 tropic (Table 7). Two HIV-1/TB (TB-1 and TB-5) had a dominance of X4 
viruses at one or both time points and three HIV-1/non TB had more than 20% of 
quasispecies X4 tropic (Table 7). In terms of subtypes, 17% of all subtype B and 
51% of subtype C were X4.      
Table 7. Co-receptor predictions of HIV-1/TB and HIV-1/non TB groups.  
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3.5. Quasispecies diversity 
Mean  intra-patient  HIV-1  diversity  was  calculated  (Table  8)  by  averaging 
distances within all the clone sequences of one individual at a single time point. 
For HIV-1/TB ranged from 1.3 to 10.3% (mean 6.37%) at the initial time point and 
2.7 to 10.1% (mean 6%) at the final time point (Table 8). For HIV-1/non TB, it 
ranged from 0.45 to 13.5% (mean 4.4%). All except two HIV-1/TB showed a very 
high diversity at the initial time point of sampling which was not observed in the 
HIV-1/non TB. An exceptionally high diversity  was observed in only one HIV-
1/non TB (NTB-3) who had been diagnosed for Toxocara canis after the time of 
sampling. When NTB-3 was excluded, a statistically significant two folds greater 
diversity was observed in the HIV-1/TB compared to HIV-1/non TB (unpaired t-
test,  p  =  0.03)  (Fig.  15).  The  increased  diversity  in  HIV-1/TB  didn’t  show 
significant reduction in the second time point sampling.  
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Figure 15 Intra-patient HIV-1 diversity of HIV-1/TB at the first time point (n = 8) and the 
second  time  point  (n=6)  compared  to  HIV-1/non  TB  at  entry  (single  time  point)  (n=7) 
showing  a  significant  difference  (p<0.05).  Evolutionary  distances  were  shown  as  the 
number of base substitutions per site using the Maximum Composite Likelihood method. 
The y-axis indicates the nucleotide distance (base substitutions per site) and the x-axis 
the group names. TP_1 = time point 1, TP_2 = time point 2.   - 45 -  Results 
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Table 8. Mean Intra-patient HIV-1 diversity, mean synonymous (ds) and non synonymous 
(dns) nucleotide substitutions, co-receptor predictions of HIV-1/TB and HIV-1/nonTB. 
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3.6. Intra-patient quasispecies diversification  
Diversification  as  defined  in  the  method  section  was  used  to  quantify  the 
dispersion  of  the  cloned  sequences  from  a fixed  single  generated  consensus 
sequence  for  each  patient  sample  at  each  time  point  (Fig.16).  Highest 
diversification  was  observed  in  patients  NTB-3  and  TB-6  (Fig.16).  For  two 
patients (TB-7 and TB-5) diversification in the two time points varied significantly. 
TB-7 showed higher diversification at the second time point compared to the first 
(p < 0.05), and TB-5 showed significantly lower diversification at the second time 
point compared to the first (p < 0.05). Although not significant (p = 0.0774), TB-3 
showed a lower diversification at the second time point compared to the first. For 
the rest of the HIV-1/TB two time point pairs, no significant difference was found.  
 
Figure 16 C2V5 env clone sequence diversification of HIV-1/TB and HIV-1/non TB. Each 
circular point indicates the pair wise comparison of the nucleotide distance of each clone 
sequence  to  a  consensus  sequence  generated  for  each  patient  sample.  The  y-axis 
indicates the sequence distance of each clone from consensus in nucleotide substitution 
per nucleotide site. The x-axis indicates the ID for each patient sample. For HIV-1/TB, in 
the time points are indicated in brackets in addition to the patient ID. TP_1 = time point 1, 
TP_2 = time point 2. 
3.7. Quasispecies divergence for HIV-1/TB 
For HIV-1/TB, quasispecies divergence, i.e., evolution of founder viruses to later 
viruses within the first and second time point sampling was calculated (Table 9). 
In patients TB-2, TB-3, TB-4, and TB-6 quasispecies that were present at the 
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initial time point were replaced by distinct quasispecies at the second time point. 
This is quite strikingly observed in patients such as TB-7 (Fig. 17). 
Mantel’s test, which compared the identity of the viral populations at two time 
points,  also  confirmed  this  observation;  in  patients  TB-1  and  TB-5,  the  viral 
population at the two time points did not show a significant difference (p > 0.05). 
In the rest of the patients, the viral population belonging to the same time point 
showed more similarity to each other than to the viral population from the other 
time point (p < 0.05). 
Table 9. Quasispecies divergence between two time points of sampling for HIV-1/TB. 
 
Rate of divergence was calculated by dividing the divergence to the time interval. 
A  higher  rate  of  divergence  was  observed  in  TB-2  (2.34  x  10
-4 
substitutions/site/day), TB-3 (8.46 x 10
-5 substitutions/site/day), TB-6 (7.9 x 10
-4 
substitutions/site/day) and TB-7 (3.05 x 10
-4 substitutions/site/day) as compared 
to  TB-1  (2.57  x  10
-5substitutions/site/day)  and  TB-5  (4.48  x  10
-6 
substitutions/site/day).Interestingly these two patients who had a slow divergence 
rate  had  a  dominance  of  X4  viruses  at  one  or  both  time  points.  - 48 -  Results 
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Figure 17 Phylogenetic analysis of C2 to V5 regions of all clones of HIV-1/TB at two time points of sampling for each patient. The trees 
show the clustering pattern of quasispecies over time. 9 to 25 clones for each time point were sequenced. The percentage of replicate 
trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) and which have values greater than 70% are 
shown. The evolutionary distances were shown as number of base substitutions per site computed using the Maximum Composite 
Likelihood method. The scale bar represents 0.1 substitutions/nucleotide site. Reference sequences from Los Alamos HIV database 
were used as out groups. Squares (□) indicate clones derived during active TB diagnosis, while black filled triangles (▲) indicate 
clones derived from samples at least 7 weeks after the start of antituberculous chemotherapy.   - 50 -  Results 
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3.9.  Synonymous  and  Non  synonymous  nucleotide 
substitutions  
Synonymous  (amino  acid  not  changing)  and  non  synonymous  (amino  acid 
changing)  nucleotide  substitutions  were  calculated  using  SNAP.  This  analysis 
gives  important  information  if  there  are  positive,  negative  or  neutral  selection 
pressures on HIV-1 viral population. As shown in Table 8 all patients except TB-
4, have greater synonymous (ds) to non synonymous (dn) substitutions and a 
ratio above one (ds/dn >1).  
3.10. Positive selection using data monkey programme 
Besides SNAP, data monkey was utilized to assess the presence of positively 
selected amino acids. Data monkey has the alternatives of three different codon-
based maximum likelihood methods, SLAC, FEL and REL, to estimate the dN/dS 
(also known as Ka/Ks or ω) ratio at every codon in the alignment. The presence 
of positively selected amino acid sites using SLAC showed no positively selected 
amino  acid  sites  for  six  of  the  HIV-1/TB  and  for  all  HIV-1/non  TB.  For  the 
remaining two HIV-1/TB patients, HXB-2 referenced gp120 amino acid positions 
466 (glutamic acid) and 467 (isoleucine) for TB-4, and 295 (asparagine) for TB-6 
were under positive selection. 
3.11. Positional variation along the C2V5 amino acid sequence 
Using Shannon entropy as a measure of variation in DNA and protein sequence 
alignments we analyzed whether there is a difference in positional variation along 
the  C2V5  env  region  of  HIV-1/TB  and  HIV-1/non  TB.  There  was  a  higher 
variability  for  HIV-1/TB  along  the  V4  region  independent  of  their  subtypes 
compared to HIV-1/non TB (Fig. 18). The median intra-patient V4 diversity for 
HIV-1/TB was 0.184 nucleotide substitutions per site (range 0.01 to 2.59) while 
for HIV-1/non TB was 0.069 nucleotide substitutions per site (range 0.0034 to 
0.2). On the other hand, the V3 diversity did not show a difference between HIV-  - 51 -  Results 
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1/TB (median 0.0363, range 0.0056 to 0.0822) and HIV-1/non TB (median 0.032, 
range 0.04 to 0.0847). 
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3.12. Potential N-linked glycosylation sites (PNGs) 
HIV env gp120 is among the most heavily
 glycosylated proteins in nature [111]. N 
linked  glycosylation,  sequon,  has  a  pattern  of  NX  [ST]  (where  X  can  be  any 
amino acid). Here we analyzed the number of PNGs for C2V5 env of HIV-1/TB 
and HIV-1/non TB by averaging the number of PNGs for each quasispecies for a 
patient at a time point. As shown in Table 10, the mean number of PNGs was 14 
(range 11 to 17) when both groups were included. No significant difference was 
found  between  HIV-1/TB  and  HIV-1/non  TB.  However,  a  significantly  lower 
number of PNGS was observed in patients with predicted X4 dominating viral 
sequences as compared to R5 (p = 0.03). 
 
 
Figure 18 Entropy plot showing variation in the amino acid sequences of clones from HIV-1/TB and HIV-1/non 
TB. Entropy >0 indicates higher variability in HIV-1/TB compared to HIV-1/non TB. Entropy <0 indicates less 
variability in HIV-1/ TB as compared to HIV-1/non TB. Significant sites with p<=0.05 are shown in red.   - 52 -  Results 
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Table  10.  Average  number  of  N-linked  glycosylation  sites  for  each  patient  obtained  by 
averaging the PNGs obtained for each clone sequence.  
 
3.13.  Correlation  between  HIV-1  viral  load,  CD4  cell  count, 
intra-patient diversity and divergence 
Viral divergence for HIV-1/TB showed a strong correlation with the initial time 
point CD4 cell count (r
2 = 0.66, p < 0.05, two tailed) (Fig. 19). No correlation was 
found between CD4 cell count and intra-patient nucleotide diversity for both HIV-
1/non TB and HIV-1/TB at the two time points of sampling. Viral load was also 
not correlated with intra-patient viral diversity for both groups.   - 53 -  Results 
________________________________________________________________ 
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Figure 19 Two time point HIV-1/TB quasispecies divergence (nucleotide substitutions/site) plotted against 
CD4 cell count (cells/µ µ µ µl) at the initial time point showing strong correlation, p<0.05.   - 54 -  Discussions 
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4. Discussion 
HIV evolves at any time over the course of an individual’s infection. Evolution of 
the virus is shaped by various selection pressures. Selection pressures can be 
exogenous in nature, such as the pressure exerted by antiretroviral drugs leading 
to the selection of drug resistance mutants; or can be endogenous, such as the 
pressure  generated  by  the  adaptive  immune  system,  leading  to  selection  of 
immune escape mutants. These two processes shape the virus in a fashion that 
may lead to individual-specific HIV-1 variants. 
In the time course of HIV infection, which is divided in to primary, asymptomatic, 
symptomatic and AIDS (Fig. 20) HIV viral variant population dynamics varies. 
During  transmission  a  dramatic  evolutionary  bottleneck  occurs,  with  ∼80%  of 
heterosexual  infections  apparently  initiated  by  a  single  variant  [113].  After 
transmission,  mutational  escape  and  reversion  rapidly  shape  HIV  evolution 
[114,115].  Especially  HIV-1–specific  CD8  T  cells  which  are  detectable  before 
seroconversion  and  long  before  neutralizing  antibodies  (NAbs)  [116]  have  an 
important contribution in shaping HIV evolution and in the decline of acute phase 
viral viremia (viral set point) [117]. 
 
During  the  asymptomatic  stage,  evolution  of  HIV  increases  rapidly.  A 
comprehensive analysis done by Shankrappa et al [66] divided HIV-1 evolution at 
this stage in to three phases quantified by diversity, divergence and emergence 
Figure 20 the typical course of HIV 
infection without intervention. 
Adapted from [112] 
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of X4 viruses. According to Shankrappa et al. [66] in the first phase, both viral 
population divergence and diversity increased linearly and in the second phase 
the viral population continued to diverge from the founder strain at the same rate, 
while  diversity  levels  off.  In  the  third  stage  divergence  also  slows  down  or 
stabilizes, while diversity declines. 
However  such  an  evolutionary  pattern  can  be  perturbed  when  the  immune 
system is activated due to infections or vaccination. Activation of the immune 
system is a normal response to antigenic stimulation which induces changes in 
the host characterized by proliferation of antigen-responsive cells, elaboration of 
cytokines,  and  subsequent  proliferation  of  bystander  cells  [118-120].  Such  a 
state  of  immune  activation  results  in  an  increase  in  the  number  of  available 
activated CD4
+ T cells that serve as susceptible targets for HIV. This leads to 
replication of HIV. 
A number of researches have addressed the issue of HIV evolutionary pattern 
during immune activation. One of the early and most prominent studies was by 
Ostrowski  et  al  [121] that characterized  HIV quasispecies  composition after  a 
shot of Tetanus Toxoid vaccine. Patients who received the vaccine showed a 
dramatic shift in composition of plasma viral quasispecies.   
Later, a study done by Collins et al. [122] was able to show influence of active TB 
on HIV quasispecies in a cross-sectional study design. In the present study, we 
were  able  to  show  effect  of  mycobacterial  growth/TB  on  HIV-1  quasispecies 
diversity on a longitudinal basis.  
The significance of our work can be viewed in the context of understanding the 
long  term  effect  of  active  TB  on  HIV-1  in  co-infected  individuals,  not  only  on 
quasispecies  evolution  but  also  on  disease  progression.  Several  reports  from 
various parts of Africa showed that the increase in HIV-1 replication due to active 
TB does not decline after 2 months of intensive antituberculous chemotherapy 
[123-125].  The  sustained  increase  in  HIV-1  replication  even  after  initiation  of 
antituberculous  chemotherapy  unlike  other  opportunistic  infections  (OIs)  [126, 
127]  is  a  puzzling  phenomenon.  The  sustainability  or  reversal  of  the  HIV-1   - 56 -  Discussions 
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quasispecies  heterogeneity  after  TB  treatment  is  not  known.  Tetanus  Toxoid 
vaccinated  HIV-1  infected  patients  developed  a  transient  increase  in  HIV-1 
heterogeneity  which  was  reversed  after  few  weeks  [121].  Emergence  of  a 
heterogeneous HIV-1 population within a patient may be one of the mechanisms 
to escape strong immune or drug pressure [65, 128]. The existence of better 
fitting  and/or  immune  escape  HIV-variants  can  lead  to  an  increase  in  HIV-1 
replication  [129,130].  It  might  be  that  TB  favourably  selected  HIV-1  variants 
which are sources for consistent HIV-1 replication.  
Understanding  the  mechanisms  underlying  the  impacts  of  TB  on  HIV-1  is 
essential  for  the  development  of  effective  measures  to  reduce  TB  related 
morbidity  and  mortality  in  HIV-1  infected  individuals.  There  are  on  going 
researches  to  find  out  the  reason  that  increased  HIV-1  replication  couldn’t 
decline  even  after  MTB  treatment  by  chemotherapy.  In  the  present  study  we 
studied whether the increase in HIV-1 quasispecies diversity during active TB is 
reversed or preserved throughout the course of antituberculous chemotherapy. 
Our investigation might partly explain the reasons for sustained HIV-1 replication 
during or after active TB treatment in antiretroviral therapy (ART) naïve patients. 
The main findings of the study are discussed here below: 
4.1. Active TB sustains HIV-1 quasispecies diversity for longer 
period 
In the present study, we compared:  
1)  HIV-1 quasispecies diversity during diagnosis and after 2 months of TB 
chemotherapy 
 2) Cloud of quasispecies during diagnosis of TB in HIV-1/TB with CD4 cell 
count matched HV-1/non TB.  
The purpose of the latter comparison was to verify whether active TB can lead to 
high HIV-1 diversity in our patients.   - 57 -  Discussions 
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 As seen in Fig. 15 HIV-1 quasispecies diversity was significantly higher (p<0.05) 
during  active  TB  and  sustained  up  to  two  months  of  chemotherapy.  This 
observation indicates that the impact of TB on HIV-1 diversity can even proceed 
after active TB treatment which is in line with other observations that showed 
HIV-1 replication remained elevated after TB resolution by chemotherapy [123-
125]. Higher diversity is usually associated with faster HIV-1 disease progression 
to AIDS [65,131].  
One way of explaining higher diversity during active TB might be generalized 
immune  activation  due  to  TB.  Infection  with  MTB  is  characterized  by  strong 
immune response. Studies in animal models and in humans have demonstrated 
that a wide range of immune components are activated during TB. These include 
T cells (both CD4+ and CD8+), cytokines, including IFN-γ, IL-12, TNFα and IL-6, 
and  macrophages  [132].  In  HIV/TB  co-infected  individuals  several  immune 
activation  markers  showed  to  increase  including  neopterin,  TNF-α,  β2-
microglobulin  [81,85,133],  various  chemokines  such  as  MIP1-α,  MIP1-β, 
RANTES  and  SDF-α  and  expression  of  chemokine  receptors  (CCR5  and 
CXCR4) [134]. 
Although  most  immune  activation  markers  are  reduced  after  start  of  TB 
chemotherapy, some might remain persistent which might lead to sustained HIV 
diversity. According to a study by Goletti et al., [82] the level of immune activation 
markers after few weeks of successful TB treatment in co-infected individuals 
had shown a decline to baseline line level in western subjects. In other studies 
some but not all immune activation markers showed a decline [85,135]. Lawn 
and colleagues [85] found out that TNFα did not show a decline after 2 months of 
chemotherapy while other activation markers showed a decline. In a study done 
in Ethiopia, Wolday and colleagues [135] did not find a reduction in the increased 
chemokine  and  chemokine  receptors  after  two  months  of  anti  tuberculosis 
chemotherapy. Kizza and colleagues [123] found two groups of patients, which 
showed  a  significant  reduction  and  those  which  did  not  after  12  months  of 
treatment follow up.   - 58 -  Discussions 
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We also asked if a more specific HIV-1 directed immune response had an impact 
on  the  observed  higher  diversity.  For  this  purpose  we  quantified  selection 
pressure. A widely used means to measure selection pressure is the analysis of 
non-synonymous  (n)  and  synonymous  (s)  nucleotide  substitutions  [60]. 
Synonymous nucleotide substitutions (s) do not change amino acid sequence 
although  there  is  a  change  at  the  nucleotide  level  whereas  non-synonymous 
substitutions  (n)  do  change  the  amino  acid  sequence.  The  ds  describes  the 
amount  of  synonymous  substitutions  that  have  occurred  in  proportion  to  all 
possible synonymous substitutions that can occur within the genetic region that is 
analyzed. A higher ds compared to dn is considered indicative of negative or 
purifying selection, which means that the gene is striving to be conserved. If dn is 
greater  than  ds  the  gene  is  under  positive  or  diversifying  selection.  A  dn  is 
probably  driven  by  selective  forces  to  change.  A  ds/dn  ratio  close  to  one 
indicates a neutralizing selection. Using this method, we obtained a ds/dn ratio 
approximately or above one for all patients which indicates that there was no 
strong positive selective pressure for all viral quasispecies isolated. This is in 
contrary to what was observed in the cross sectional study by Collins et al [122].   
4.2. Active TB increases rate of HIV-1 divergence  
When we quantified an average rate of C2V5 evolution in two time point follow-
up of HIV-1/TB, we found an average rate of 2.4 x 10
-4 substitutions/site/day. We 
compared this value with an average rate of env evolution from previous reports 
[136-140] .The average rate of genetic evolution of HIV-1 was estimated to be 
2.3 x 10
-3 to 6.7 x 10
-3 substitutions/site/year
 at the env V3 region, while the rate 
for  the  whole env  was  1.0  x  10
-3 and 1.7 x  10
-3 substitutions/site/year,  which 
gives  an  approximation  of  1.7  x10
-5  substitutions/site/day.  Compared  to  these 
previous  reports,  our  HIV-1/TB  patients  had  14  times  higher  mutation  rate. 
However, we were unable to compare the rate with HIV-1/non TB group due to 
their immediate start of HAART before second time point sampling.   - 59 -  Discussions 
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A higher viral divergence and divergence rate might indicate high replication and 
constant  pressure  for  evolution.  It  is  also  clearly  demonstrated  in  the 
phylogenetic trees reconstructed. For example in patient TB-3 (Fig. 17), the viral 
quasispecies composition at time point 2 is distinct from that of time point 1 within 
only 7 weeks. At longer time interval, approximately 43 weeks, in patient TB-7 a 
separation of two clusters of viral population was observed (Fig. 17).Especially, 
four of the six patients: TB-7, TB-2, TB-6, TB-3 had a higher evolutionary rate 
compared to the remaining two.  
4.3. TB might lead to slow evolution of X4 variants  
Using phyletic analysis by Mantel’s test, we obtained a significant difference in 
genetic identity between quasispecies at TP-1 and TP-2 in four of the six HIV-
1/TB.These patients namely: TB-7, TB-2, TB-6 and TB-3 had also a dominance 
of predicted R5 phenotype. In the residual two (TB-1 and TB-5), no significant 
difference in quasispecies identity between the two time points and a dominance 
of X4 viruses was observed.  
In one in vitro study [134] it was observed that MTB increased CXCR4 surface 
expression on alveolar macrophages and allowed the entry and replication of X4 
viruses  while  inhibiting  R5  virus  entry.  Some  earlier  studies  indicated  that 
macrophages  exposed  to  mycobacterial  cell  wall  lipoarabinomannan  become 
highly  susceptible  to  HIV-1  [141].  It  was  further  demonstrated  that  stimulated 
macrophages are highly susceptible to T-tropic HIV-1 (which otherwise poorly 
replicate in macrophages) and modestly susceptible to M-tropic HIV-1 [141]. At 
advanced  stages  of  HIV  disease  the  source  of  HIV  replication  are  tissue 
macrophages [142].  
The observation that slower divergence rate and similar viral population for a 
long period of time in the samples of HIV-1/TB with dominance of X4 viruses 
might be related to the direct selective pressure of MTB to HIV-1 to favorably 
select X4 viral populations. The proportion of X4 viruses, however, in all our HIV-  - 60 -  Discussions 
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1/TB  patients  remained  stable  over  the  study  period,  which  might  be  due  to 
tuberculosis chemotherapy and needs further study. 
4.4. Other findings 
Besides the above mentioned findings, our study highlighted findings such as, 
the high variation of V4 loop in HIV-1/TB compared HIV-1/non TB. V4 as part of 
the env loop is likely to have an impact on Env conformation and glycan packing 
[143-145] although its role in neutralization resistance is not clear. In one study it 
was found that C3 and V4 regions combine to form important structural motifs 
and  that  epitopes  in  this  region  are  major  targets  of  the  early  autologous 
neutralizing response in HIV-1 subtype C infection [146]. 
In the present study, the numbers of N-linked glycosylation sites along the C2V5 
were  lower  in  X4  viruses  compared  to  R5.  This  observation  is  in  line  with 
previous  reports  that  demonstrated  that  decreased  number
  of  N-linked 
glycosylation  sites  (sequons)  in  gp120,  especially
  within  and  around  the  V3 
region, during
 evolution from the R5 to the X4 phenotype [147-149]. 
From our intra-patient diversity data (Table 8) and diversification plot (Fig. 16) 
one can see that single time point sequence diversification is variable. Even in 
HIV-1/TB there were individuals who showed extremely low intra-patient diversity 
like TB-7 and TB-5. As may be seen, this is independent of the duration of HIV-1 
infection and HIV-1 subtypes. It might be that the initial time point sampling was a 
few months earlier than the diagnosis of active tuberculosis (approximately 5 and 
4 months respectively). As MTB is a slow growing bacterium we assumed that 
these patients had TB infection even at that earlier time.  
The observation that there was no difference in diversity and divergence between 
African origin patients living in Europe and native Europeans indicates that the 
country of origin and viral subtypes have no significant impact on the influence of 
TB on HIV-1 diversity. In our study, the HIV-1 viral load in HIV-1/TB patients after 
the  start  of  antituberculous  chemotherapy  did  not  show  a  significant  decline   - 61 -  Discussions 
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compared to untreated TB. Similar observations in HIV-1/TB co-infected patients 
in Africa were frequently reported [123-125]. 
Although the sample size for the African participants in this study was small (n 
=4),  we  also  observed  the  onset  of  active  TB  in  African  origin  patients  at  a 
significantly higher CD4 cell count compared to European origin patients. This 
observation is in line with studies done in TB endemic countries, where the onset 
of TB occurs at higher CD4 cell
 counts [150,151] which might be explained by the 
reactivation of childhood tuberculosis in Africans. 
4.5. Limitations of the study 
Our study  has  a clear  limitation to  find control  patients who  fulfilled  selection 
criteria such as matched CD4 cell count without opportunistic infections (OI) and 
with follow-up. Although we made efforts, it was difficult to find HIV-1 infected 
individuals with no other co-infection at CD4 cell count below 200 per µl. Control 
subjects such as NTB-1, NTB-3 and NTB-4 had documented co-infections like 
Candida albican and T.canis. Intra-patient viral diversity in these patients was 
higher than the residual 5 and was comparable to the HIV-1/TB subjects. This 
might  suggest  that  OI  can  trigger  HIV-1  sequence  diversity.  Besides  an 
extremely high HIV-1 diversity was observed in one control subject (NTB-3). HIV-
1 from this control subject showed the highest diversity of all the others. More 
than half of the quasispecies isolated from the sample of this patient harboured a 
predicted X4 phenotype. No other opportunistic infection has been documented 
except T. canis. Until to date, there are no reports which indicate the possible 
association  of  T.canis  infection  with  HIV-1  genetic  diversity.  The  possible 
association of this helminthic infection with HIV needs further investigation. 
The strategy used in our study to isolate HIV-1 quasispecies is one of the few 
available methods used in many laboratories to date. It is however linked with 
method-specific  limitations  such  as  Taq  induced  recombination,  nucleotide 
misincorportion, template resampling and cloning bias [152]. Primers used in the 
study  were  tested  for  different  subtypes  and  their  priming  regions  are  at  low   - 62 -  Discussions 
________________________________________________________________    
mutable or constant regions of HIV-1 C2C5 env. However, one cannot assure 
that all the quasispecies templates were amplified.   - 63 -  Summary 
________________________________________________________________ 
   
Summary 
One  of  the  earliest  and  most  striking  observations  made  about  HIV  is  the 
extensive genetic variation that the virus has within individual hosts, particularly 
in  the  hypervariable  regions  of  the  env  gene  which  is  divided  into  5  variable 
regions (V1-V5) and 5 more constant (C1-C5) regions.  
HIV evolves at any time over the course of an individual’s infection and infected 
individuals harbours a population of genetically related but non-identical viruses 
that  are  under  constant  change  and  ready  to  adapt  to  changes  in  their 
environment.  These  genetically  heterogeneous  populations  of  closely  related 
genomes are called quasispecies [65].  
Tuberculosis  or  tubercle  forming  disease  is  an  acute  and/or  chronic  bacterial 
infection that primarily attacks the lungs, but which may also affect the kidneys, 
bones,  lymph  nodes,  and  brain.  The  disease  is  caused  by  Mycobacterium 
tuberculosis  (MTB),  a  slow  growing  rod-shaped,  acid  fast  bacterium.  It  is 
transmitted  from  person  to  person  through  inhalation  of  bacteria-carrying  air 
droplets. 
Worldwide, one person out of three is infected with Mycobacterium tuberculosis – 
two  billion  people  in  total.  TB  currently  holds  the  seventh  place  in  the  global 
ranking of causes of death [73]. In 2008, there were an estimated 9.4 (range, 
8.9–9.9  million)  million  incident  cases  (equivalent  to  139  cases  per  100  000 
population) of TB globally [75].   
A complex biological interplay occurs between M. tuberculosis and HIV in co-
infected host  that results  in  the  worsening of  both pathologies.  HIV  promotes 
progression of M. tuberculosis either by endogenous reactivation or exogenous 
reinfection [77, 78] and, the course of HIV-1 infection is accelerated subsequent 
to the development of TB [80].  
Active  TB  is  associated  with  an  increase  in  intra-patient  HIV-1  diversity  both 
systemically and at the infected lung sites [64,122]. The sustainability or reversal 
of  the  HIV-1  quasispecies  heterogeneity  after  TB  treatment  is  not  known.   - 64 -  Summary 
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Tetanus toxoid vaccinated HIV-1 infected patients developed a transient increase 
in HIV-1 heterogeneity which was reversed after few weeks [121]. Emergence of 
a  heterogeneous  HIV-1  population  within  a  patient  may  be  one  of  the 
mechanisms to escape strong immune or drug pressure [65,128]. The existence 
of better fitting and/or immune escape HIV-variants can lead to an increase in 
HIV-1  replication  [129,130].  It  might  be  that  TB  favourably  selected  HIV-1 
variants which are sources for consistent HIV-1 replication.  
Understanding  the  mechanisms  underlying  the  impacts  of  TB  on  HIV-1  is 
essential  for  the  development  of  effective  measures  to  reduce  TB  related 
morbidity  and  mortality  in  HIV-1  infected  individuals.  In  the  present  study  we 
studied whether the increase in HIV-1 quasispecies diversity during active TB is 
reversed or preserved throughout the course of antituberculous chemotherapy.  
For  this  purpose  Two  time  point  HIV-1  quasispecies  were  evaluated  by 
comparing HIV-1 infected patients with active tuberculosis (HIV-1/TB) and HIV-1 
infected  patients  without  tuberculosis  (HIV-1/non  TB).  Plasma  samples  were 
obtained from the Frankfurt HIV cohort and HIV-1 RNA was isolated. C2V5 env 
was amplified by PCR and molecular cloning was performed. Eight to twenty five 
clones were sequenced from each patient. Various phylogenetic analyses were 
performed including tree inferences, intra-patient viral diversity and divergence, 
selective pressure, co-receptor usage prediction and two time point identity of 
quasispecies comparison using Mantel’s test. 
We found out from this study that: 
1) Active TB sustains HIV-1 quasispecies diversity for longer period 
2. Active TB increases the rate of HIV-1 divergence  
3) TB might slow down evolution of X4 variants 
And  we  concluded  that  active  TB  has an  impact  on  HIV-1  viral  diversity  and 
divergence over time. The influence of active TB on longitudinal evolution of HIV-
1 may be predominant for R5 viruses. The use of CCR5-coreceptor inhibitors for 
HIV-1/TB  patients  as  therapeutic  approach  needs  further  investigation.  - 65 -  Zusammenfassung 
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Zusammenfassung 
Eine der ersten und überraschenden Beobachtungen, welche bei der Analyse 
des  HI-Virus  gemacht  wurden  ist  seine  ausgeprägte  Genetische  Variabilität 
besonders die hypervariable Region des env Genes betreffen. Dieses wird in 5 
variable  Regionen  (V1-V5)  sowie  5  stärker  konservierte  Regionen  (C1-C5) 
unterteilt. 
HIV wandelt sich zu jedem Zeitpunkt im Verlauf der Infektion und jedes infizierte 
Individuum ist Träger einer Population von genetisch verwandten jedoch nicht 
identischen Viren, welche sich kontinuierlich verändern und an die Erfordernisse 
innerhalb der Umgebung anpassen. Diese genetisch heterogenen, jedoch eng 
verwandten Populationen werden Quasispecies genannt.  
Tuberkulose  ist  eine  mykobakterielle  Infektion,  welche  sowohl  akute  als  auch 
chronische  Verläufe  zeigt.  Neben  den  Lungen  als  primärem  Manifestationsort 
können auch die Nieren, Knochen und andere Organe befallen sein. Eine von 
drei Personen weltweit ist mit Mycobacterium tuberculosis infiziert, insgesamt 2 
Milliarden Menschen.  
In  HIV/TB  Co-Inifzierten  Menschen  entsteht  ein  komplexes  Zusammenspiel 
zwischen  HIV  und  M.  tuberculosis,  welches  zu  einer  Verschlechterung  beider 
Krankheitsbilder  führt.  HIV  führt  durch  endogene  Rekativierung  oder  exogene 
Re-Infektion zu einer Progression der Tuberkulose, welche im weiteren Verlauf 
die  Krankheitsprogression  von  HIV  beschleunigt.  Sowohl  Morbidität  als  auch 
Mortalität sind in HIV-1/TB Co-Infizierten Menschen erhöht.  
Aktive  Lungentuberkulose  und  Miliartuberkulose  gehen  mit  dem  Anstieg  der 
Diversifität der HIV Viren innerhalb eines Wirtes einher. Wie lange diese erhöhte 
Heterogenität  der  HIV  Quasispecies  nach  der  erfolgreichen  Behandlung  einer 
Tuberkulose bestehen bleibt ist bisher noch unklar.  
Das Verständnis des dem Zusammenspiel von HIV und TB zugrundeliegenden 
Mechanismus ist essentiell für die Entwicklung von effektiven Massnahmen zur 
Senkung der Morbidität und Mortalität in HIV/TB Co-infizierten Menschen.    - 66 -  Zusammenfassung 
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Die  gegenwärtige  Forschungsarbeit  folgte  daher  der  Frage,  ob  wärend  einer 
aktiven  TB  Infektion  eine  Zunahme  der  Diversität  der  HIV-1  Quasispecies  zu 
beobachten ist und ob diese Diversität während einer TB Therapie erhalten bleibt 
oder sich zurück bildet.  
Hierfür wurden die HIV-1 Quasispecies zu zwei Zeitpunkten untersucht, wobei 
Proben von HIV-1 infizierten Patienten mit aktiver Tuberkulose (HIV-1/TB) und 
HIV infizierte Patienten ohne Tuberkulose  (HIV-1/non TB) verglichen wurden. 
Aus Plasmaproben der Frankfurter HIV Cohorte wurde HIV-1 RNA isoliert. C2V5 
env  wurde  durch  PCR  amplifiziert  und  molekular  cloniert.  Acht  bis 
fünfundzwanzig  Clone  wurden  für  jeden  Patienten  sequenziert.  Mehrere 
phylogenetische  Analysen  wurden  durchgeführt,  welche  tree  inferences,  Intra-
Patienten-  und  virale  Diversität  und  Divergenz,  Selektionsdruckanalysen, 
Vorhersage der Co-Rezeptornutzung sowie Zweipunktanalysen der Identität von 
Quasispecies mit Hilfe des Mantel’s Test miteinschlossen. 
Die Analysen ergaben die folgenden Ergebnisse: 
1) Eine aktive TB erhält die Diversität von HIV-1 Quasispecies über einen 
längeren Zeitraum.  
2.  Eine aktive TB verstärkt die HIV -1 Divergenz  
3) TB könnte zu einer langsameren Evolution von X4 Varianten führen.  
Schlussfolgerung:  eine  aktive  TB  beeinflusst  die  Entwicklung  der  viralen 
Diversität und Divergenz von HIV-1 im Verlauf der Krankheit. Der Einfluss der 
aktiven TB auf die longitudinale Evolution von HIV-1 könnte insbesondere R5 
Viren betreffen. Der Einsatz von CCR5-Corezeptor Inhibitoren in HIV-1/TB co-
inifizerten Patienten sollte daher in Langzeitstudien untersucht werden.  
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Abbreviations 
 
AIDS  Acquired Immunodeficiency Syndrome 
ART  Antiretroviral therapy 
ARVs   AIDS-associated retroviruses 
bp  base pair 
BLAST        Basic local alignment searching tool 
Cat No        Catalogue number 
CCR5  CC Chemokine Receptor 5 
CDC  Center for disease control 
cDNA  complementary DNA 
CRF  Circulating Recombinant Form 
CXCR4  CXC chemokine Receptor 4 
dn  the relative proportion of non-synonymous substitution 
DNA  Deoxyribonucleic acid 
DDBJ         DNA Data Bank of Japan 
ds  the relative proportion of synonymous substitution 
Env  envelop 
EPTB  Extra pulmonary tuberculosis 
E.coli  Escherichia Coli 
EMBL  European Molecular Biology Laboratory 
EU          European Union 
FEL  fixed effects likelihood 
Gag  Group specific antigen 
gp  Glycoprotein 
HAART  Highly active antiretroviral therapy 
HBCs  high-burden countries 
HIV  Human Immunodeficiency virus 
HIVCENTER  HIV Treatment and Research Unit   - 82 -  Appendix 
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HMMs          Hidden Markov models 
HXB2          Name of HIV-1 M subtype B reference strain 
HTLV-III        human T-cell leukemia virus III 
ICTV  International Committee on Taxonomy of Viruses 
IFNγ  Interferon γ 
IL-1  Interleukin 1 
IL-2  Interleukin 2 
IL-6  Interleukin 6 
IL-12  Interleukin 12 
kb  kilobases 
LTR  Long Terminal Repeats 
LAV           Lymphadenopathy associated virus 
LB         Luria-Bertani 
MIP-1        Macrophage Inflammatory Proteins 
MEGA          Molecular evolutionary genetics analysis 
MTB  Mycobacterium tuberculosis 
Nef  Negative factor 
NFκB  Nuclear factor Kappa B 
NSI  Non-syncytium Inducing 
NJ  Neighbour joining 
NCBI          National Center for Biotechnology Information 
NTB          HIV-1/non TB patient groups 
PBMC  Peripheral Blood Mononuclear cells 
PCR  Polymerase chain reaction 
Pol  polymerase 
POP  performance optimized polymer 
PND              principal neutralizing domains 
PNGs            Potential N-linked glycosylation sites 
PTB  Pulmonary tuberculosis 
RANTES   Regulated upon Activation, Normal T-cell Expressed, and    
Secreted 
REL  random effects likelihood 
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Rev  Regulator of virion protein 
R/H  Rapid/High 
RNA  Ribonucleic acid 
RT  Reverse transcriptase 
RT-PCR  Reverse transcriptase PCR 
SI  Syncytium Inducing 
S/L  Slow/low 
SIV  Simian Immunodeficiency Virus 
SLAC  Single Likelihood Ancestor Counting 
SDF-α  stromal-derived factor-&alpha 
Tat   transactivator of transcription 
TB  Tuberculosis 
TB -            HIV-1/TB (for this particular study) 
TP           Time point (for this particular study) 
TNFα  Tumor necrosis factor α 
URFs  unique recombinant forms 
Vif  Virion infectivity factor 
Vpr          Viral protein R 
Vpu                   Viral protein U 
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